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Abstract
Substance abuse is a major public health burden, accounting for significant social, physical, and health
problems and resulting in considerable health care costs. Screening, Brief Intervention, and Referral to
Treatment (SBIRT) is a public health approach that provides early intervention for individuals with risky
alcohol and drug use and timely referral to specialty substance abuse treatment for individuals with
substance use disorders. This observational study utilized a single group pre-post test design to test the odds
of admission to specialty substance abuse treatment based on severity of substance involvement as
determined by the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). A secondary
aim was to assess differential effects in admission to specialty treatment based on age, gender,
race/ethnicity, ASSIST severity, alcohol and/or other substance reported, pre-SBIRT mental health
treatment, and pre-SBIRT specialty substance abuse treatment among study participants who received a BI
or BI/RT.

Significant effect was found for study participants who screened at high-risk on the ASSIST for alcohol
and/or other substances and who were offered a BI/RT and who had a pre-SBIRT admission to specialty
treatment. The odds of the BI/RT study participants (OR= 4.751; 95% CI 2.634, 8.571) with prior substance
abuse treatment having a post-SBIRT admission to specialty treatment was 4.751 times greater than the
odds of study participants who did not have prior substance abuse treatment admission. The role of BI and
the substantially significant role of BI/RT, as components of SBIRT, are confirmed as a promising approach
for early intervention for substance use disorders.

Impact of Brief Interventions on Admissions to Specialty Substance Abuse Treatment

Sabrina Trocchi
B.A., University of Connecticut, 1994
M.P.A., University of Hartford, 1996

A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy
at the
University of Connecticut
2018

i

Copyright by
Sabrina Trocchi
2018

ii

APPROVAL PAGE
Doctor of Philosophy Dissertation
Impact of Brief Interventions on Admissions to Specialty Substance Abuse Treatment

Presented by
Sabrina Trocchi, MPA

Major Advisor:

_____________________________________________
Thomas Babor, PhD, MPH

Associate Advisor:

_____________________________________________
Richard Fortinsky, PhD

Associate Advisor:

_____________________________________________
James Grady, PhD

Associate Advisor:

_____________________________________________
Bonnie McRee, PhD

Associate Advisor:

_____________________________________________
Jane Ungemack, PhD

University of Connecticut
2018

iii

ACKNOWLEDGEMENTS
I would like to thank all the wonderful individuals who have supported and encouraged me
throughout my academic career. To my husband, Rick, and three children, Emily, Tessa, and
Jacob, who were with me throughout this journey, I owe you extreme gratitude for your patience
and encouragement. For the countless missed dinners while I was attending evening courses; for
the ski trips in Vermont where I sacrificed and stayed back in the warm cabin to do work while
you all ventured in the freezing, cold mountain; for the missed movie nights as I sat with my
laptop—I thank you for your unwavering support, encouragement and love! And huge thank you
to my mentor, Dr. Thomas A. Kirk, Jr., who encouraged me to always strive for greater things.

I would like to acknowledge my dissertation committee members, beginning with my dissertation
Committee Chair, Dr. Thomas Babor. Dr. Babor’s commitment to the addiction field and to the
highest standards has motivated me to pursue and excel in the doctorate program. I would also like
to thank committee members Dr. Fortinsky, Dr. Grady, Dr. McRee, and Dr. Ungemack for their
leadership, expertise and applied knowledge. To Dr. McRee, I am especially grateful for the initial
nudge to apply to the Doctoral program and your ongoing guidance throughout this journey. Thank
you for believing in me.

iv

I would like to thank the Connecticut Screening, Brief Intervention, and Referral to Treatment (CT
SBIRT) Program staff, including the Department of Mental Health and Addiction Services
(DMHAS) staff, Health Educators, and the CT SBIRT Program evaluation staff for their level of
commitment in developing, implementing and evaluating the CT SBIRT Program. Without you
all I would not have had the data needed to complete my dissertation. I want to especially thank
Janice Vendetti, MPH, from the UCHC CT SBIRT Evaluation Team for her support with the data,
data analysis, and her SPSS expertise.

v

DEDICATION
I dedicate this dissertation to my husband, Rick, and three children—Emily, Tessa, and Jacob, for
their enduring love and support throughout this long yet rewarding journey.

vi

TABLE OF CONTENTS	
  	
  
TABLE OF CONTENTS ......................................................................................................... vii  
FIGURES ..................................................................................................................................ix  
CHAPTER 1: INTRODUCTION ................................................................................................ 1  
CHAPTER 2: LITERATURE REVIEW ..................................................................................... 8  
2.1. Public Health Effects of Alcohol and Illicit Drug Use ........................................................... 9  
2.2. Prevalence Rates of Alcohol and Illicit Drug Use ............................................................... 10  
2.3. Benefits of Treatment ......................................................................................................... 12  
2.4. Barriers to Treatment.......................................................................................................... 13  
2.5. SBIRT: A Public Health Approach ..................................................................................... 14  
2.6. Brief Intervention (BI) Theory and Frameworks ................................................................. 18  
2.7. Effectiveness of Brief Interventions for Alcohol and Other Drugs ...................................... 21  
2.8. Role of Brief Interventions on Treatment Admissions ........................................................ 24  
2.9. Conceptual Framework ...................................................................................................... 26  
2.10. Study Hypothesis and Secondary Exploratory Aim........................................................... 28  
CHAPTER 3: METHODS ........................................................................................................ 30  
3.1. Overview of the Connecticut SBIRT Program .................................................................... 31  
3.2. Overview of Study Design.................................................................................................. 32  
3.3. Study Locations.................................................................................................................. 32  
3.4. Participant Sample and Eligibility ...................................................................................... 34  
3.5. Screening, Brief Intervention, and Referral to Treatment (SBIRT) Procedures.................... 35  
3.6. Data Sources ...................................................................................................................... 41  
3.7. Data on Screened Sample ................................................................................................... 42  
3.8. Eligible Study Participants ................................................................................................. 44  
3.9. Data Analyses .................................................................................................................... 47  
CHAPTER 4: RESULTS .......................................................................................................... 49  
4.1. Overview ........................................................................................................................... 49  
4.2. Study Hypothesis ............................................................................................................... 49  
4.3. Secondary Exploratory Aim ............................................................................................... 52  
CHAPTER 5: DISCUSSION .................................................................................................... 58  
5.1. Overview ........................................................................................................................... 58  
5.2. Substance Abuse, SBIRT & Specialty Treatment ............................................................... 59  
5.3. Study Hypothesis ............................................................................................................... 60  
5.4. Secondary Exploratory Aim ............................................................................................... 63  
vii

5.5. Strengths and Limitations of Dissertation Study ................................................................. 65  
5.6. Public Health Implications ................................................................................................. 67  
5.7. Future Research.................................................................................................................. 68  
5.8. Conclusion ......................................................................................................................... 69  
APPENDICES .......................................................................................................................... 69  
APPENDIX 1: WHO ASSIST .................................................................................................. 70  
APPENDIX 2: Scoring the ASSIST .......................................................................................... 76  
REFERENCES ......................................................................................................................... 77  

viii

FIGURES

Figure 1 Guiding Framework for Study ......................................................................... 27  
Figure 2 CT SBIRT Program Study Design--Patient Flow............................................. 36  
Figure 3 Flow Diagram for Study Participants............................................................... 46

ix

TABLES
Table 1 CT SBIRT Program Patient Screening Data...................................................... 32  
Table 2 Patient Demographics for Community Health Centers FY 2012 ....................... 33  
Table 3 ASSIST Tool Substances List ........................................................................... 38  
Table 4 ASSIST Screening Risk Scores and Indicated Intervention ............................... 39  
Table 5 Administrative Data Sources ............................................................................ 42  
Table 6 Characteristics of Unduplicated Screened Sample............................................. 43  
Table 7 Characteristics of Unduplicated, Eligible Study Sample (N=3,931) .................. 45  
Table 8 Predicting Odds of Admission to Specialty Treatment (n = 3,937) .................... 51  
Table 9 Predicting Differential Effects of Independent Variables on Admission to Specialty
Treatment (n = 3,937) ................................................................................................... 53  
Table 10 Cross Tabulation of Pre- and Post-SBIRT Specialty Treatment for Study Participants
Offered BI or BI/RT...................................................................................................... 54  
Table 11 Specialty Treatment Pre-SBIRT vs. Post-SBIRT ............................................ 55  
Table 12 Specialty Treatment Pre-SBIRT vs. Post-SBIRT Odds Ratio .......................... 56  
Table 13 Community Health Centers with On-Site Specialty Treatment ........................ 57  

x

CHAPTER 1: INTRODUCTION
Substance abuse is a major public health burden, accounting for significant social, physical, and
health problems and resulting in considerable health care costs. In 2014, an estimated 136.9 million
Americans, aged 12 and older, were identified as current alcohol users, with 22.9% classified as
binge drinkers, defined as drinking five or more drinks for males and drinking four or more drinks
for females on the same occasion on at least one day in the past 30 days, and 6.3% as heavy
drinkers, defined as binge drinking on five or more days in the past 30 days based on the thresholds
described above for males and females (Substance Abuse and Mental Health Services
Administration (SAMHSA), 2014). Additionally, an estimated 24.6 million Americans, aged 12
or older, were identified as current illicit drug users, meaning they had used an illicit drug during
the month prior to the survey interview (SAMHSA, 2014). Treatment need was identified by
classifying survey respondents as having a substance use disorder in the past 12 months based on
broad criteria specified in the most recent Diagnostic and Statistical Manual of Mental Disorders
edition (DSM). Diagnosis criteria included symptoms such as withdrawal, tolerance, use in
dangerous situations, trouble with the law, and interference with major obligations at work, school,
or home during the past 12 months (SAMHSA, 2014). In 2013, an estimated 22.7 million
individuals or 8.6 percent of the population, aged 12 or older, needed treatment for alcohol or an
illicit drug problem. Of the estimated 22.7 million Americans who were classified as needing
treatment, only about 2.5 million people 10 percent received treatment in a specialty substance
abuse treatment facility, of which 859,000 received treatment for alcohol use, 899,000 received
treatment for illicit
1

drug use only, and 633,000 received treatment for both alcohol and illicit drug use (SAMHSA,
2014). It is worthy to mention that treatment need was based on a very broad definition of
substance use disorder, which included a significant number of individuals who are at low levels
of dependence.

A large body of scientific evidence demonstrates that substance abuse treatment is generally
associated with positive outcomes for individuals with substance use disorders, including reduced
future medical costs and arrests and higher likelihood of employment (McLellan et al., 1994;
Campbell et al., 2007; Luchanksy et al., 2006; Wickizer, et al., 2000; Wickizer et al., 2006).
Research shows that the earlier substance-dependent individuals engage in treatment, the faster
and better the outcomes (Timko et al. 1999; Moos & Moos 2003), further highlighting the
significance of identifying substance use/abuse issues early (universal screening) and intervening
with clinically indicated interventions (motivationally based brief interventions and/or referral to
specialty treatment). While scientific data suggests that specialty treatment increases the likelihood
of recovery among individuals with diagnosable dependence (Dawson et al., 2006), a number of
barriers prevent individuals from seeking, entering, and remaining in treatment. Screening, Brief
Intervention, and Referral to Treatment (SBIRT) is a public health approach that provides early
intervention for individuals with risky alcohol and drug use and timely referral to specialty
substance abuse treatment for individuals with substance use disorders. Although SBIRT programs
vary, key SBIRT components generally include universal screening, motivationally based brief
interventions (BIs), and referral to specialty substance abuse treatment services (RT) for
individuals presenting at
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higher risk for alcohol and/or other substance use. SBIRT is largely delivered in primary healthcare
settings, such as community health centers, hospital emergency departments, and dental clinics.
While there is substantial evidence of the short-term benefits of BI for alcohol problems, tobacco
use and other health risk behaviors in primary care settings (Babor et al., 2007), less is known on
the extent to which BIs are associated with admissions to specialty substance abuse treatment
services. Therefore, this dissertation was designed to examine factors associated with patient
engagement in specialty substance use treatment for those receiving SBIRT services within a
primary care visit at one of nine (9) Federally Qualified Health Centers across Connecticut.

SBIRT services include use of validated, universal screening tools to identify all psychoactive
substances with determination of level of risk. Patients screening negative or low-risk for
substances are provided education and feedback about those substances. The Connecticut SBIRT
Program utilized the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) to
obtain risk level (no risk, low-risk, moderate-risk or high-risk) for alcohol and/or substance misuse.
The ASSIST was developed by the World Health Organization (WHO) specifically for use in
primary healthcare settings where harmful substance use among patients may go undetected.
Validity of the ASSIST for identifying substance use in individuals who use a number of
substances and have varying degrees of substance use has been demonstrated in a number of multisite international studies (Humeniuk et al., 2007).

It was demonstrated that the ASSIST can discriminate between low-, moderate-, and high-risk
substance use across multiple substances, including alcohol, cannabis, opioid, and cocaine use
(Humeniuk et al., 2007). Patients scoring in the moderate risk range are offered a BI to encourage
3

lower risk use, while those scoring in the high risk range are offered a BI and a referral to treatment
(RT) to motivate them to engage in specialty treatment. BIs are widely researched methods shown
to provide risk reduction to patients at lower or moderate levels of risk and are also used to
encourage high-risk individuals to accept more intensive treatment. BIs encompass several broad
frameworks and theories on behavioral change and motivation, including Stages of Change,
FRAMES (Feedback, Responsibility, Advice to Change, Menu of Options, Empathy, and SelfEfficacy), and Motivational Interviewing (MI) theories, all of which are considered to account for
the observed changes in substance use, although there is little evidence that these components are
necessary or sufficient conditions for behavior change.

Based on the growing literature on BIs (Krupski, et al., 2010; Babor et al., 2007; SAMHSA, 2011),
including reported effects of BIs, as a component of SBIRT, in treatment engagement, this study
was designed to test the odds of admission to specialty substance abuse treatment based on severity
of substance involvement and the receipt of BI or BI/RT interventions. The study hypothesis was
based on the assumption that study participants who screened at high-risk on the ASSIST for
substance use and were offered a BI/RT would be more likely to engage in specialty substance
abuse treatment within a year post-SBIRT intervention compared to those who screened at
moderate-risk on the ASSIST and received a BI only. Study participants who screened at high-risk
and who were offered BI/RT, which facilitates engagement into specialty substance abuse
treatment, would present to specialty substance abuse treatment at higher rates than study
participants who screened at moderate-risk on the ASSIST. A secondary exploratory aim was to
assess differential effects in admission to specialty treatment based on age, gender, race/ethnicity,
ASSIST severity, alcohol and/or other substance reported, pre-SBIRT mental health treatment, and
4

pre-SBIRT specialty substance abuse treatment among study participants based on the receipt of a
BI or BI/RT.

The following analyses were conducted to test the study hypothesis and exploratory secondary
aim:

1)   The first analysis tested the odds of admission to specialty substance abuse treatment based
on severity of substance involvement and the receipt of BI or BI/RT as part of health center
SBIRT services within the previous year.

2)   The second (exploratory) analysis investigated demographic, including age, gender,
race/ethnicity, alcohol and/or other substance reported, pre-SBIRT mental health
treatment, and pre-SBIRT specialty substance abuse treatment and ASSIST severity
correlates of treatment engagement among study participants based on the receipt of a BI
or BI/RT.

This was an observational study which utilized a single study group pre-post test design to test the
odds of admission to specialty substance abuse treatment based on severity of substance
involvement and the receipt of BI or BI/RT interventions. Specialty substance abuse treatment
was defined as an admission to a licensed substance abuse treatment program within 365 days (one
year) post-SBIRT intervention as captured by the Connecticut Department of Mental Health and
Addiction Services (DMHAS) client database. Specialty substance abuse treatment included the
following levels of care: residential detoxification, long-term rehabilitation, intensive and
5

intermediate residential, medication assisted treatment, including methadone maintenance,
outpatient, and partial hospitalization. This study relied on existing administrative data from a
number of sources, including the Connecticut Department of Mental Health and Addiction
Services (DMHAS) administrative database and the Connecticut SBIRT Program database.

The study population included adults, ages 18 and over, who presented at one of the nine
community health centers implementing the CT SBIRT Program between March 1, 2011 and
March 31, 2013 and who screened at moderate-risk or at high-risk on the ASSIST for alcohol
and/or other substances and who were offered a BI or BI/RT. Individuals who screened at lowrisk on the ASSIST were provided feedback by the Health Educators (HEs) on their ASSIST score
and what it represents, in addition to being provided a positive educational message and
encouragement to continue their healthy behaviors. No further action was taken with individuals
who screened at low-risk. Individuals who screened at moderate-risk or at high-risk on the ASSIST
were asked permission to discuss their substance use, and, if the participant was willing, moved
into a BI. Participants in the high-risk group, in addition to receiving a BI, were also referred to
specialty substance abuse treatment (RT) for additional assessment and possible placement in an
appropriate level of care. Admission to specialty substance abuse treatment was determined by
matching study participant identifiers to the Connecticut Department of Mental Health and
Addiction Services (DMHAS) administrative database of specialty substance abuse treatment.

As hypothesized, the odds of the BI/RT study population having a post-SBIRT admission to
specialty treatment was 2.78 times greater than the odds of study participants who screened at
moderate-risk and who were offered a BI only [OR= 2.78; 95% CI 2.27, 3.40]. When factoring
6

age, gender (male), race/ethnicity, prior history of mental health treatment, prior history of
substance abuse treatment, and ASSIST severity scores, the odds of the BI/RT study participants
having a post-SBIRT admission to specialty treatment was between 2.88 and 1.67 times higher
than for the BI only study participants. These findings indicate that BI/RT, as a component of the
SBIRT model, could potentially impact admissions to specialty substance abuse treatment postSBIRT intervention more significantly than BI alone. It is also important to note that BI alone also
had a positive impact on admissions to specialty substance abuse treatment. Significant effect was
found for study participants who screened at high-risk on the ASSIST for alcohol and/or other
substances and who were offered a BI/RT and who had a pre-SBIRT admission to specialty
treatment. The odds of the BI/RT study participants with prior substance abuse treatment having a
post-SBIRT admission to specialty treatment was 4.751 times greater than the odds of study
participants who did not have prior substance abuse treatment admission [OR= 4.75; 95% CI 2.63,
8.57]. No significant effects were predicted for BI or BI/RT and age, gender, race/ethnicity or prior
mental health treatment, where each characteristic was examined one-by-one to measure the
independent effects on post-SBIRT admission to specialty substance abuse treatment.

The potential for BIs, as a component of SBIRT, to identify, intervene, and motivate individuals
at-risk for alcohol and/or other substances to access specialty treatment could have a significant
impact on healthcare given continued trends of alcohol and/or other substance abuse in the United
States. The findings of this dissertation study have the potential to affirm a significant role for BIs,
as a component of SBIRT, in motivating and facilitating individuals’ admission to specialty
treatment.

7

SBIRT provides early identification and intervention with individuals who are at risk for substance
abuse. The role of BI and substantially significant role of BI/RT, as components of SBIRT, in
increasing access to specialty substance abuse treatment is promising. Wider dissemination of BI
and BI/RT, as components of SBIRT, can have a significant impact on healthcare and societal
costs associated with substance abuse. The potential for BIs, as a component of SBIRT, to identify,
intervene, and motivate individuals at-risk for alcohol and/or other substances to access specialty
treatment could have a significant impact on healthcare given continued trends of alcohol and/or
other substance abuse in the United States.

CHAPTER 2: LITERATURE REVIEW
This chapter reviews the literature for the key domains that support the study aims and hypotheses
tested. Domains include: 1) Public Health Effects of Alcohol and Illicit Drug Use; 2) Prevalence
Rates of Alcohol and Illicit Drug Use; 3) Benefits of Substance Abuse Treatment; 4) Barriers to
8

Treatment; 5) Screening, Brief Intervention and Referral to Treatment (SBIRT): A Public Health
Approach; 6) Brief Intervention (BI) Theory; 7) Effectiveness of Brief Interventions (BIs) with
Alcohol and Other Drugs; and 8) Role of Brief Interventions (BI) in Specialty Treatment
Admission. This chapter concludes with a conceptual framework and rational for this dissertation
study, including scientific gaps and a description of the study aims and hypotheses.

2.1. Public Health Effects of Alcohol and Illicit Drug Use
Substance abuse is a major public health burden, accounting for significant social, physical, and
health problems and resulting in considerable health care costs. Substance abuse often results in
poor health outcomes and substantial costs related to illnesses, hospitalizations, motor vehicle
injuries, and premature deaths. Deaths resulting from alcohol and illicit drugs use, most of which
are preventable, include unintentional overdose, suicide, HIV and AIDS acquired through the
sharing of contaminated drug paraphernalia, and trauma, such as, motor vehicle accidents caused
by driving under the influence (United Nations Office of Drugs and Crime (UNODC), 2014). In
the United States, the total costs of abuse and addiction due to use of alcohol and illicit drugs are
estimated at $740 billion a year in health care, productivity loss, crime, and incarceration and drug
enforcement (National Institute on Drug Abuse (NIDA), 2013). Alcohol accounts for 5.9% of the
world's annual disease burden and contributes to 3.3 million deaths annually (WHO, 2014).
Globally, it is estimated that in 2010 between 153 million and 300 million people aged 15-64; or
3.4-6.6 percent of the world’s population in that age group, had used an illicit substance at least
once in the previous year. Illicit drugs contribute to an additional 250,000 deaths annually (WHO,
2012), with drug-related deaths accounting for 0.5 and 1.3 percent of all-cause mortality among
those aged 15-64 (UNODC, 2014).
9

2.2. Prevalence Rates of Alcohol and Illicit Drug Use
The National Survey on Drug Use and Health (NSDUH) is the primary source of statistical
information on the use of alcohol and illicit drugs by the U.S. civilian, non-institutionalized
population aged 12 or older (SAMHSA, 2014). The survey is sponsored by SAMHSA, U.S.
Department of Health and Human Services, and is planned and managed by SAMHSA's Center
for Behavioral Health Statistics and Quality (CBHSQ). According to the 2013 NSDUH, an
estimated 136.9 million Americans aged 12 and older were current alcohol users, with 22.9%
classified as binge drinkers and 6.3% as heavy drinkers. Binge drinking is defined as drinking five
or more drinks for males and drinking four or more drinks for females on the same occasion on at
least one day in the past 30 days. Heavy drinking is defined as having five or more drinks on the
same occasion on at least five days in the past 30 days (SAMHSA, 2014). Additionally, an
estimated 24.6 million Americans aged 12 or older were current illicit drug users, meaning they
had used an illicit drug during the month prior to the survey interview. This estimate represents
9.4 percent of the population aged 12 or older (SAMHSA, 2014). Illicit drugs include
marijuana/hashish,

cocaine,

heroin,

hallucinogens,

inhalants,

or

prescription-type

psychotherapeutics (pain relievers, tranquilizers, stimulants, and sedatives) used for non-medical
purposes. The data indicates that marijuana use has continued to increase, where 19.8 million
persons reported current (past-month) use (7.5 percent); 6.5 million reported nonmedical users of
prescription-type drugs (2.5 percent); 1.5 million reported cocaine use (.6 percent); and an
estimated 289,000 current heroin users (.1 percent) of the population. After alcohol, marijuana has
the highest rate of dependence or abuse among all drugs, with 4.3 million Americans meeting
clinical criteria for dependence or abuse of marijuana in 2012. More than half (52.1 percent) of
10

Americans aged 12 or older reported being current drinkers of alcohol, translating to an estimated
135.5 million current drinkers in 2012 (SAMHSA, 2012). An estimated 21.6 million persons aged
12 or older (8.2%) in 2013 were classified with substance dependence or abuse in the past year
based on criteria specified in the Diagnostic and Statistical Manual of Mental Disorders, 4th
edition (DSM-IV).

Analysis of the National Household Survey on Addictions (SAMHSA, 2014) shows that
Connecticut has: 1) a higher rate of alcohol use, binge drinking, and illicit drug use than the
national average. Connecticut’s rate of substance abuse or dependence (10.1%) is higher than the
nation as a whole (9.2%); 2) an estimated 268,000 adults have a current need for treatment for
substance abuse or dependence; 3) a higher rate of past month use of alcohol than the national
average (60.8% vs. 51.4%); 4) a higher rate of binge drinking than the national average (25.1% vs.
22.9%); and 5) a higher rate of illicit drug use (9.2%) in the past month than the national average
(8.2%). The Connecticut DMHAS Annual Statistical Report provides information about the
services provided and the individuals served during state fiscal year 2015 (CT DMHAS, 2016).
During State Fiscal Year 2015 (July 1, 2014 through June 30, 2015), 59,203 individuals were
treated in specialty substance abuse treatment programs. The most common primary drug at
admission was heroin/other opiates at 52.6%, followed by alcohol at 29.1%, marijuana at 9.2%,
and cocaine at 5.4% (CT DMHAS, 2016). More than twice as many male patients (68%) presented
to specialty substance abuse treatment than female patients (31%). Of patients served, 64% were
White/Caucasian, 16% Black/African American, and 14% of Hispanic ethnicity. The average age
of patients receiving specialty substance abuse treatment services was 38.3 years. Admissions to
specialty substance abuse treatment levels of care were as follows: 9% Residential/Inpatient, 64%
11

Outpatient, and 27% Medication Assisted Treatment, including Methadone Maintenance. The
Connecticut substance abuse treatment system includes approximately 51 licensed substance abuse
treatment organizations with over 300 programs.

The Affordable Care Act (ACA) created changes in the delivery and funding of specialty substance
abuse treatment services, including increasing the number of individuals that are eligible to receive
these services. In Connecticut, the Medicaid Expansion in 2012 resulted in an increased number
of individuals eligible for Medicaid. In FY 13, the number of uninsured was approximately 13.2%
of the state’s population and this was reduced to approximately 4% in 2015 (CT DMHAS, 2016).

2.3. Benefits of Treatment
The goal of specialty substance abuse treatment, in addition to stopping or decreasing the
frequency of substance use, is to return individuals to productive functioning in the family,
workplace, and community. Participation with substance abuse treatment is generally associated
with positive outcomes for individuals with substance use disorders (McLellan, et al., 1994), with
a large body of scientific evidence demonstrating that substance abuse treatment is associated with
reduced future medical costs and arrests, higher likelihood of employment, and improved social
and psychological functioning (Campbell et al., 2007; Luchanksy et al., 2006; Wickizer, et al.,
2000; Wickizer et al., 2006). According to the National Institute on Drug Abuse (NIDA), specialty
substance abuse treatment reduces drug use by 40 to 60 percent and arrest rates for violent and
nonviolent criminal acts by 40 percent during and after treatment (NIDA, 2016). Furthermore,
research shows that specialty substance abuse treatment reduces the risk of HIV infection and can
improve the prospects for employment, with gains of up to 40 percent after treatment (NIDA,
12

2016). Effective treatment includes medication and behavioral therapy, often in combination, to
ease withdrawal symptoms and increase skills to handle cues that may trigger substance abuse and
prevent relapse. Research shows that the earlier substance-dependent individuals engage in
treatment, the faster and better the outcomes (Timko et al. 1999; Moos & Moos 2003), further
highlighting the significance of delivering SBIRT services in primary health care settings to
identify substance use/abuse issues early (universal screening) and intervene with clinically
indicated interventions, i.e., motivationally based brief interventions and/or referral to specialty
treatment.

2.4. Barriers to Treatment
In 2013, an estimated 22.7 million individuals, or 8.6 percent of the population, aged 12 or older,
needed treatment for alcohol or an illicit drug problem (SAMHSA, 2014). It is worthwhile to
mention that treatment need was based on a very broad definition of substance use disorder, which
included a significant number of individuals who are at low levels of dependence. Of the estimated
22.7 million Americans who were classified as needing treatment, only about 2.5 million people
(10 percent) received treatment at a specialty substance abuse treatment facility, of which 859,000
received treatment for alcohol use, 899,000 received treatment for illicit drug use only, and
633,000 received treatment for both alcohol and illicit drug use (SAMHSA, 2014). Among the
20.2 million individuals who did not receive treatment at a specialty facility, 908,000 or 4.5 percent
reported that they perceived a need for treatment. Of the 908,000, 316,000 individuals or 34.8
percent reported they made an effort to get treatment and 592,000 or 65.2 percent reported making
no effort to get treatment (SAMHSA, 2014). Commonly reported reasons for not receiving
treatment include: 1) no health coverage/could not afford treatment cost (37.3 percent); 2) not
13

ready to stop using (24.5 percent); 3) did not know where to access treatment (9.0 percent); 4) had
health coverage but it did not cover treatment cost (8.2 percent); and 5) no transportation or
treatment facility offered inconvenient hours for services (8.0 percent) (SAMHSA, 2014).

While scientific data suggests that treatment increases the chance of recovery among individuals
with diagnosable dependence (Dawson et al., 2006), there are a number of barriers that prevent
individuals seeking, entering, and remaining in treatment. Internal barriers include guilt, stigma,
shame, feelings of powerlessness and hopelessness, access to treatment services, and lack of
confidence that treatment will work (Grant, 1997; George & Tucker, 1996). External barriers
include lack of knowledge regarding treatment availability and fear of the behavioral health
treatment and legal systems (Coletti, 1998), in addition to fragmentation of services (Finkelstein,
1993). Literature on the process for referring individuals to assessment and specialty substance
abuse treatment suggests that brief interventions (BIs) may be critical for the following reasons:
1) many individuals with alcohol and/or drug dependence do not seek treatment on their own until
reaching a state of extreme severity; 2) most individuals do not follow up on a recommendation to
seek treatment and BIs have been shown to increase the number who enter specialized substance
abuse treatment; and 3) motivationally based BIs for individuals with substance use disorders not
only facilitate their entry into treatment but also increase their treatment participation, attendance,
and retention (Babor et al., 2007).

2.5. SBIRT: A Public Health Approach
As described on the federal Center for Substance Abuse Treatment (CSAT) website, “SBIRT is a
public health approach to the delivery of early intervention and treatment services for people with
14

substance use disorders and those at risk of developing these disorders. Many different types of
community settings provide opportunities for early intervention with at-risk substance users before
more severe consequences occur” (SAMHSA, accessed May 14, 2014). Since 2003, SAMHSA
has awarded cooperative agreements to twenty-nine states, one territory, and two tribal councils to
establish SBIRT services. The SAMHSA-funded SBIRT Programs are designed to expand States’
continuum of care to include services for at-risk substance users to reduce alcohol and drug
consumption and its negative health impact, reduce costly health care utilization, and promote
sustainability. The World Health Organization (WHO), in response to the growing global crisis
resulting from alcohol and illicit drugs use, strongly recommends that screening for harmful
alcohol and illicit drug use be conducted using a validated instrument that can easily be
incorporated into routine primary care practice and that individuals with harmful alcohol and/or
drug use be provided brief interventions (BIs) (WHO, 2013). The U.S. Preventive Services Task
Force (USPSTF), an independent panel of experts in prevention and evidence-based medicine, has
recommended that primary care clinicians provide BIs to reduce alcohol misuse among adults ages
18 and older (USPSTF, 2004). SBIRT, which is identified as a promising practice for addressing
unhealthy alcohol and/or illicit substance use in patient populations, was also a key component of
the 2011 and 2012 National Drug Control Strategy (Office of National Drug Control and Policy
(ONDCP), 2011, 2012a).

Although SBIRT programs vary, key SBIRT components generally include universal screening,
motivationally based brief interventions, and referral to specialty substance abuse treatment
services, as defined below. SBIRT is largely delivered in primary healthcare settings, such as
community health centers, hospital emergency departments, and medical and dental clinics.
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I.  

Universal Screening: Screening is the process of identifying individuals with potential
substance misuse or abuse problems and determining the appropriate interventions or next
steps for these individuals. Screening is conducted using a validated brief instrument to classify
an individual’s pattern of alcohol or drug use (SAMHSA, 2013). Several examples of validated
instruments include the Alcohol Use Disorders Identification Test (AUDIT) (Babor, HigginsBiddle, Saunders, & Monteiro, 2001), the Drug Abuse Screening Test (DAST) (Skinner,
1982), the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)
(Humeniuk, Henry-Edwards, Ali, Poznyak, & Monteiro, 2010). Screening offers the
opportunity to initiate discussions with individuals about their alcohol and drug use and to
provide interventions as recommended. Individuals who have a low screening score may not
need an intervention, but may still benefit from health education and prevention activities to
further support maintenance of low-risk use behaviors. Individuals who have a moderate
screening score may be provided a motivationally based BI to raise individuals’ awareness of
their substance use and its consequences and motivate them towards positive change.
Individuals who score high may receive a BI and/or be referred to specialty substance abuse
treatment (RT) for further diagnostic assessment.

II.  

Brief Interventions (BIs): BIs are evidence-based procedures that provide immediate attention
to individuals who screen at moderate-risk and high-risk for alcohol and/or other substance use
behaviors. As defined in the SAMHSA Treatment Improvement Protocol (TIP), BIs are timelimited, structured, and directed interventions, which aim to raise individuals’ awareness of
substance use and its consequences and motivate them towards positive change (SAMHSA,
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1999). The intensity and focus of the BI is driven by the individual’s presenting risk level and
the patient’s degree of readiness for behavior changes. In general, BIs in primary healthcare
settings can range from 3 to 30 minutes of brief feedback, counseling, and advice (WHO,
2010). Key to the success of BIs is the ability to identify a measurable behavioral change that
allows individuals to experience a small, incremental success. These small successes generally
motivate individuals to return for more successes (SAMHSA, 1999). In low-risk users, the
goal of BI is to educate them on the guidelines for low-risk use and potential problems of
increased use. For example, an individual screening low-risk for alcohol use, should be
encouraged to stay within empirically established guidelines—no more than 14 drinks per
week or 4 per occasion for men and no more than 7 drinks per week or 3 per occasion for
women (NIAAA, website 2015). In moderate-risk users, defined as individuals who are above
the recommended guidelines for alcohol use or whose substance use places them at risk, the
goal of BI is to address the level of use, to encourage decreased use or no use, and to educate
the individual about the consequences of risky behavior and continued increased use. In highrisk users, defined as individuals with a likely substance use disorder per the most recent
Diagnostic and Statistical Manual of Mental Disorders (DSM), the goal of BI is to prevent an
increase in substance use, to educate on the consequences of risky behavior, and to encourage
the individual to consider assessment or specialty substance abuse treatment. Furthermore, for
these individuals BIs facilitate referrals to specialty treatment services and have the potential
to move individuals towards seeking treatment (Bien et al., 1993). While BIs are not a
substitute for individuals who screen high enough to be classified as being at high-risk for
substance use, they may be used to engage patients into specialized substance abuse treatment
services. Furthermore, BIs are seen as complementary to the continuum of substance abuse
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treatment options, particularly valuable when an individual is resistant to needed specialty
substance abuse treatment. BIs can also improve individual’s compliance with specialty
treatment by focusing on attainable goals.

III.  

Referral to Treatment (RT): Effective BI approaches incorporate comprehensive, proactive
strategies to refer high-risk individuals to specialty substance abuse treatment (Babor et al.,
2007). The goal of the referral component is to identify appropriate specialty substance abuse
treatment providers and to facilitate engagement of individuals in treatment. The SBIRT Health
Educator provides a quick hand-off of individuals to specialty substance abuse treatment
providers. To facilitate individual engagement, SBIRT providers use motivational
enhancement techniques to encourage individuals with ambivalence towards treatment
(SAMHSA, 2013). Research findings suggest that motivational-based BIs can increase
individual participation and retention in specialty substance abuse treatment (Dunn & Ries,
1997).

2.6. Brief Intervention (BI) Theory and Frameworks
This dissertation was designed to establish an association between BI and admission to specialty
substance abuse treatment. BIs encompass several broad frameworks and theories on behavioral
change and motivation, including Stages of Change, FRAMES (Feedback, Responsibility, Advice
to Change, Menu of Options, Empathy, and Self-Efficacy), and Motivational Interviewing (MI)
theories, which are considered to account for the observed changes in substance use, although there
is little evidence that these components are necessary or sufficient conditions for behavior change.
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I.

The Stages of Change model, which helps tailor interventions to individuals' needs
(Prochaska and DiClemente, 1984), provides a useful framework for understanding the
process by which people change their behavior and for considering how ready they are to
change their substance use behaviors. This model is the work of Prochaska and DiClemente
who examined several theories concerning behavior change and how it applies to substance
abuse behavior modification. Their Stages of Change model, comprised of five stages—Precontemplation, Contemplation, Preparation, Action and Maintenance—represents the
process individuals go through when thinking about, beginning and trying to maintain new
behavior (WHO, 2010). With regard to BIs, Stages of Change model is useful in tailoring
interventions to individual’s current level of readiness for change (Hodgson and Rollnick,
1992; Mudd et al., 1995). Individuals are offered motivational supports appropriate to their
Stage of Change. For each level of Stages of Change, a different stage of action is
recommended. Pre-contemplation Stage: The majority of individuals screened through
SBIRT are likely to be in this stage. Individuals at this stage are not thinking about changing
their substance use, are focused on the positive aspects of their substance use, and are
unlikely to have concerns about their substance use (SAMHSA, 1999). For individuals at the
pre-contemplation stage, the role of the BI is to raise their awareness of substance use/abuse.
Contemplation Stage: Individuals in the contemplation stage are thinking about reducing or
stopping substance use and are likely to have some awareness of the problems associated
with substance use. A proportion of people in the contemplation stage may be willing to
make a change but they may not know how to make a change (SAMHSA, 1999). For
individuals at contemplation stage, the role of BI is to help these individuals choose positive
change over their current behaviors, help in identifying and choosing change strategies, and
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help to carry out and comply with the change strategies (SAMHSA, 1999). Preparation /
Determination Stage: Individuals in this stage are intending to act, may make small changes
in their substance use behaviors, and are considering the options available, including
specialty treatment. Action Stage: It is anticipated that a smaller portion of individuals are in
this stage. Individuals in this stage have made the decision to change substance use behavior
and are actively taking steps to do so. Maintenance Stage: Individuals in the maintenance
stage are attempting to maintain gains made in substance use behavior and are working
towards preventing relapse. With comprehension of the five stages within the Stages of
Change model, SBIRT staff are able to accept the individual's current stage, avoid "getting
too far ahead" of where the individual is, and, most important, apply the most appropriate BI
strategy for each stage of readiness (SAMHSA, 1999).

II.  

BIs also employ the FRAMES (Feedback, Responsibility, Advice to Change, Menu of
Options, Empathy, and Self-Efficacy) model. The components of FRAMES include: (1)
Feedback. Individuals are shown their alcohol and/or drug screening scores using a feedback
card and are provided an explanation of what these scores mean. (2) Responsibility. A key
principle with substance users is that they acknowledge and accept that they alone are
responsible for their own behavior (SAMHSA, 1999). The BI emphasizes the individual’s
responsibility and choice for reducing use. (3) Advice. A central component of effective BIs
is the provision of clear advice, delivered in a non-judgmental manner, on how to reduce the
harms associated with continued use. Individuals may be unaware that their current pattern
of substance use could lead to health or other problems or make existing problems worse.
Advice to change, i.e., information on safe drinking guidelines, is provided in a manner that
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involves the individual in setting their individual goals. (4) Menu of options. Individuals are
offered a variety of change options from which they may choose. These may include setting
specific limits, learning to avoid high-risk situations or developing skills to avoid use. (5)
Empathy. A core training component for SBIRT staff is focused on maintaining empathy and
avoiding confrontation. Delivery of BIs utilizes a non-confrontational, reflective style which
is more effective than an aggressive, confrontational style. (6) Self Efficacy. BIs include
motivation-enhancement techniques to encourage individuals to develop, implement and
commit to plans to stop and or reduce risky substance use (SAMHSA, 1999).

III.

BIs utilize a motivational interviewing (MI) (Miller & Rollnick, 2002) approach to help
individuals evaluate the pros and cons of their substance use and level of concern. This
includes immediate feedback on substance abuse scores, risks associated with pattern of
use/abuse, advice on self-directed options for change, and motivation to change one’s
behavior. Feedback about the use of the primary substance identified through the highest
score is given and behavioral change strategies are offered.

2.7. Effectiveness of Brief Interventions for Alcohol and Other Drugs
BIs are based on over 30 years of research supporting their efficacy for alcohol use reduction,
risk reduction, and cost reduction. The efficacy of BI in primary care settings has been supported
by randomized controlled trials in both Europe and the United States (Wilk et al., 1997; Wallace
et al., 1998; Fleming et al., 1997, 2002; Whitlock et al., 2004; Bertholet et al., 2005). BI
approaches have been successfully implemented in large-scale health systems (Gelber & Renaldo,
2000), and have been demonstrated to be effective across racial and ethnic groups (Latinos,
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Whites, African Americans), age groups (young adults, older adults), substance use disorders
(alcohol, tobacco, and other drugs) and settings (e.g., community health centers, hospitals). BIs
have also proven to be cost-effective, resulting in a reduction of about $4 in health care
expenditures for every dollar spent (Fleming, et al., 2000; 2002). The Washington State SBIRT
program demonstrated a reduction in total Medicaid costs, ranging from $185-$192 per month,
for individuals who received a BI (Estee et al., 2006). A study by Gentitello et al., (2005) showed
that every $1.00 spent on providing screening and BIs resulted in approximately $3.81 in savings.

BIs for alcohol use have shown effectiveness in reducing hazardous drinking (Kaner et al., 2007),
as well as in reducing medical costs (Estee et al., 2010; Fleming et al., 2000). In a Cochrane Review
of the effectiveness of BIs for alcohol consumption in primary care populations, Kaner and
colleagues (2009) analyzed 22 randomized clinical trials enrolling 7,619 participants and showed
that participants receiving BIs had lower alcohol consumption than the control group after followup of one year. Moreover, BIs have been shown to be effective in reducing alcohol misuse. Bien
et al. (1993) evaluated 32 controlled studies involving over 6,000 patients, finding that BIs with
problem drinkers were often as effective as more extensive treatments. Twelve randomized
controlled trials were reviewed by Wilk et al. (1997), who found that drinkers receiving a BI were
twice as likely to reduce their alcohol use over 6 to 12 months as those who received no
intervention. Fleming et al., (1997) in a clinical trial conducted in community-based primary care
practices to test the efficacy of brief physician advice in reducing alcohol use by problem drinkers,
found that both treatment and control group participants reduced their number of drinks in the past
seven days and reduced their number of binge drinks in the past 30 days. Additionally, the
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percentage of people who drank excessively in the past seven days was lowered for both treatment
and control groups.

Literature on the effectiveness of BIs for risky drug use (Madras et al., 2008; Saitz et al., 2010)
continues to grow, with a number of randomized studies finding statistically significant effects,
with several exceptions as noted below. A randomized controlled trial of BI for illicit drugs linked
to the ASSIST administered to patients in primary health care settings (Humeniuk et al., 2011)
indicated that ASSIST screening linked to BI has potential to reduce substance use and substance
use disorders in a wide variety of primary health care settings. Another randomized controlled trial
indicated that BIs were associated with reductions in cocaine and heroin use (Bernstein et al.,
2005) and BIs have been linked with reductions in marijuana, cocaine, and heroin use (Madras et
al., 2008). BIs were associated with a reduction in illicit drug and alcohol abuse after 6-months in
a random sample of patients (Madras et al., 2009). SAMHSA funded SBIRT projects have also
reported significant reductions in drug use and other problems from baseline to follow-up
(Gryczynski et al., 2011; InSight 2009; Woodruff et al., 2013). However a recent study by RoyByrne et al. (2014) to determine whether BI improves drug use outcomes compared with care as
usual found that a one-time BI had no effect on drug use in patients. A similar study by Saitz et al.
(2014) which tested the efficacy of BIs for unhealthy drug use compared with no BI, also did not
find efficacy in use of BI for decreasing unhealthy drug use in primary care patients. A systematic
review by Young et al. (2014), which assessed the effectiveness of BIs in reducing nonmedical
use of psychoactive substances, found insufficient evidence to support whether BIs, as part of
SBIRT, are effective or ineffective for reducing use of nonmedical psychoactive substances when
administered to a non-treatment seeking population.
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While several studies have attempted to identify factors that result in different responses to BI by
client characteristics, most studies of BIs to date are limited by their lack of sufficient subject
assessments post-BI intervention. Findings from the available research suggest that client
characteristics are not good predictors of a person's response to a BI and that BIs may be relevant
to individuals from a wide range of cultures and backgrounds (SAMHSA, 1999).

In summary, BIs for alcohol and/or substance misuse are critical to the prevention of and/or early
intervention in addiction. For individuals at-risk of developing a serious problem with drinking or
drugs, the identification of early warning signs can be enough to change risky drinking or drug use
habits. For others, BIs may be important first steps toward treatment of and recovery from
addiction. There is substantial evidence of the benefits of BIs for alcohol problems and other health
risk behaviors in primary care settings (Babor et al., 2007). There is also promising evidence
suggesting that BIs could be effective for drug abuse (Babor et al., 2007; Madras et al., 2009;
Gryczynski et. al., 2011; InSight, 2009; Woodruff et al., 2013). Given the large population who
engages in risky substance use, BIs could have significant public health implications and positively
impact a broad population with risky substance use.

2.8. Role of Brief Interventions on Treatment Admissions
The reported effects of BIs on treatment engagement vary widely. In individual studies, BIs have
increased the percent of individuals who show up for their first clinic appointment from 5% among
controls to 50 to 65% among those receiving BIs, with as many as 50% of individuals reporting
that they continue to be involved in some kind of substance abuse treatment or 12-step meetings
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on follow-up (Bernstein et al., 1997; D’Onofrio et al., 1998; Dunn and Ries, 1997). Bien and
colleagues examined 12 controlled studies of strategies to improve individuals' acceptance of
referrals for additional specialist treatment or return to the clinic for additional treatment following
an initial visit. They concluded that relatively simple strategies and specific aspects of counselors'
styles can increase rates of follow through on referrals as well as improve initial engagement and
participation in treatment (Bien et al., 1993). Bien and colleagues concluded from an analysis of
three other studies that BIs enhanced the motivation of treatment-seeking problem drinkers to enter
and remain in outpatient or residential alcohol treatment compared with individuals not receiving
such attention (Bien et al., 1993). In addition to being helpful in providing individuals
encouragement and information about substance abuse and substance abuse treatment, BIs serve
as a means of motivating individuals to seek specialty treatment.

Literature on the process for referring individuals to specialty substance abuse treatment suggests
that BIs may be critical in linking individuals to specialty substance abuse treatment services for
the following reasons: 1) screening in high volume primary care settings offers greater opportunity
to engage individuals who are in need of intervention (Agerwala et al, 2012); 2) many individuals
with alcohol and/or drug dependence do not seek treatment on their own; and 3) motivationally
based BIs for individuals with substance use disorders not only facilitate their entry into treatment
but also increase their treatment participation, attendance, and retention (Babor et al., 2007). For
those at risk of developing a serious problem with drinking or drugs, the identification of early
warning signs can be enough to change negative drinking or drug use. For others, BIs are important
first steps toward treatment of and recovery from addiction. In summary, there is evidence that BIs
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are effective with at-risk and hazardous substance users, and emerging evidence suggests that BIs
can be used to motivate individuals to seek specialized substance abuse treatment.

Clinical evidence also suggests that BIs can be used in specialized treatment programs to address
specific targeted issues. A study by Longabaugh et al., 2010 found that a booster session, following
BI or BI/RT, enhanced the effect of the BI. A booster session was defined as a ten-minute followup call approximately one week after the initial intervention and included motivational
interviewing to follow-up on patient ambivalence to commit to the intervention.

2.9. Conceptual Framework
Review of existing literature illustrates the limited research on BI and its impact on admissions to
specialty substance abuse treatment. A systematic review in 2010 of randomized controlled trials
of BI found no studies that examined linkage to specialty treatment as a study outcome (Saitz,
2010). Several other systematic reviews that evaluated the effect of BIs on subsequent health
utilization did not specifically examine utilization of specialty treatment (Bray et al., 2011; Mdege
et al., 2013). Existing reviews of BI have not provided adequate evidence to inform whether or
not BIs increase subsequent specialty treatment utilization. Building upon the significant
knowledge base acquired in the studies of BIs in primary care settings and a growing literature that
focuses on the public health outcomes of BIs, this study is guided by the treatment systems
framework, adapted from the work of Babor et al. (2008), which was based on the public health
approach to specialty treatment systems. This framework takes into consideration how other
services and supports interact with and complement specialized treatment. The framework begins
with system policies which are the higher level decisions made by policymakers that influence the
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continuum of services/interventions adopted in the treatment system. In this instance, the State of
Connecticut adopted the implementation of SBIRT. The system characteristics include the
availability of and access to SBIRT services. The federal funding garnered by DMHAS to support
the CT SBIRT Program provided the resources needed to train a workforce and implement SBIRT
across the nine targeted community health centers in Connecticut. Treatment policies, system
characteristics, and effectiveness of SBIRT services were expected to contribute to increased
admissions to specialty substance abuse treatment. The treatment systems framework suggests
that BIs would motivate individuals found to be at-risk for substance use to present to a specialty
substance abuse treatment provider and potentially have a positive impact on population health,
such as earlier identification of substance use/abuse risk, increased admissions to specialty
substance abuse treatment, and improved social and health outcomes. Figure 1 illustrates the
guiding framework for the study.

Figure 1 Guiding Framework for Study
Treatment
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Policies supporting
adoption of SBIRT
Factors
in Connecticut’s
Continuum of
Treatment

Structural
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-Federal CT SBIRT
Program funding
-Access to SBIRT in 9
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Effectiveness of BI
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Characteristics: Race/
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-Improved health and
social outcomes

Population Impact

2.10. Study Hypothesis and Secondary Exploratory Aim
Based on the growing literature on BIs (Krupski et al., 2010; Babor et al., 2007; SAMHSA, 2011),
including reported effects of BIs as a component of SBIRT in treatment engagement, the primary
aim of this study was to test the odds of admission to specialty substance abuse treatment taking
into account severity of substance involvement and the receipt of BI or BI/RT interventions. The
study hypothesis was based on the assumption that study participants who screened at high-risk
on the ASSIST for substance use and were offered a BI/RT would be more likely to engage in
specialty substance abuse treatment within a year post-SBIRT intervention compared to those who
screened at moderate-risk on the ASSIST and received a BI only. Study participants who screened
at high-risk and who were offered BI/RT, which facilitates engagement into specialty substance
abuse treatment, would present to specialty substance abuse treatment at higher rates than study
participants who screened at moderate-risk on the ASSIST. A secondary exploratory aim was to
assess differential effects in admission to specialty treatment based on age, gender, race/ethnicity,
ASSIST severity, alcohol and/or other substance reported, pre-SBIRT mental health treatment, and
pre-SBIRT specialty substance abuse treatment among study participants based on the receipt of a
BI or BI/RT.

The following analyses were conducted to test the study hypothesis and exploratory secondary
aim:
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1)   The first analysis tested the odds of admission to specialty substance abuse treatment based
on severity of substance involvement and the receipt of BI or BI/RT as part of health center
SBIRT services within the previous year.

2)   The second analysis investigated the effects of demographic characteristics, including age,
gender, race/ethnicity, alcohol and/or other substance reported, pre-SBIRT mental health
treatment, and pre-SBIRT specialty substance abuse treatment and ASSIST severity
correlates of treatment engagement among study participants based on the receipt of a BI
or BI/RT.

This study has the potential to inform clinical practice and health care policy, particularly with a
focus on increasing efforts to implement SBIRT in various health care settings. The contention
that BIs, as a component of SBIRT, may motivate individuals screening at-risk for alcohol and/or
other substances to seek specialty treatment underscores the importance of further examining the
role of BIs in increasing admissions to specialty treatment.
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CHAPTER 3: METHODS
This study was an observational study which utilized a single study group pre-post test design to
test the odds of admission to specialty substance abuse treatment based on severity of substance
involvement and the receipt of BI or BI/RT interventions. A secondary aim was to assess
differential effects on admission to specialty treatment based on age, gender, race/ethnicity,
ASSIST severity, alcohol and/or other substance reported, pre-SBIRT mental health treatment, and
pre-SBIRT specialty substance abuse treatment among study participants based on the receipt of a
BI or BI/RT. This study relied on existing administrative data from a number of sources, including
the CT DMHAS administrative database of specialty substance abuse treatment and the CT SBIRT
Program database (described below). This chapter describes: 1) the CT SBIRT Program; 2) study
design; 3) study locations; 4) participant sample and eligibility; 5) BI procedures; 6) data sources;
7) preliminary data on study participant sample; 8) eligible study participants; 9) data analysis 10)
power analysis; and 11) Human Subjects Protections.
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3.1. Overview of the Connecticut SBIRT Program
In 2011, the State of Connecticut DMHAS was awarded a five-year grant in the amount of $8.3
million from the federal SAMHSA, Center for Substance Abuse Treatment (CSAT), to establish a
statewide SBIRT program. The purpose of the Connecticut SBIRT Program, in response to the
SAMHSA initiative goals, was to: 1) expand the state's continuum of care to include SBIRT
services in general medical and other community settings; 2) support clinically appropriate BIs for
individuals screening at moderate- or high-risk for alcohol and/or other substances; 3) improve
linkages between community agencies performing SBIRT and specialty substance abuse treatment
agencies; and 4) identify systems and policy changes to increase access to treatment in generalist
and specialist settings. A program evaluation, conducted by the University of Connecticut Health
Center (UCHC), focused on monitoring the implementation of the SBIRT program to reduce
alcohol and drug consumption and its negative health impact among patients presenting for
primary health care and examining service implementation models for sustainability purposes. In
addition to conducting the evaluation activities, UCHC, through the establishment of an SBIRT
Training Institute, provided training and supervision to the Connecticut SBIRT Program staff,
comprised primarily of health educators, in addition to technical assistance to staff at the
participating community health centers.

The Connecticut SBIRT Program employed the following components: 1) universal screening to
identify level of risk; 2) motivational-based BI driven by level of risk; and 3) referral to treatment
as indicated. Between October 1, 2011 and August 31, 2016, the Connecticut SBIRT Program
screened a total of 69,521 patients across the nine targeted community health center sites.
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Summary of risk-levels of screened patients is presented in Table 1 below. Of the 69,521 patients
screened, 61,397 (88.3%) screened at low-risk, 7,120 (10.2%) screened at moderate-risk, and
1,004 (1.4%) screened at high-risk. All patients who screened at moderate-risk were offered a BI.
Patients screening at high-risk were offered a BI in addition to being offered a brief treatment
and/or referral to a specialty substance abuse treatment (RT).

Table 1 CT SBIRT Program Patient Screening Data
October 1, 2011—August 31, 2016
Patients who Screened at Low-Risk for Alcohol/Drug Use
Patients who Screened at Moderate-Risk for Alcohol/Drug Use
Patients who Screened at High-Risk for Alcohol/Drug Use

Total
Number
61,397
7,120
1,004
69,521

Percent
88.3%
10.2%
1.4%
100%

*CT DMHAS/SBIRT Website (Retrieved 10/4/2017)

3.2. Overview of Study Design
This study utilized a single study group pre-post test designed to test the odds of admission to
specialty substance abuse treatment based on severity of substance involvement and the receipt of
BI or BI/RT interventions. A secondary aim was to assess differential effects in admission to
specialty treatment based on age, gender, race/ethnicity, ASSIST severity, alcohol and/or other
substance reported, pre-SBIRT mental health treatment, and pre-SBIRT specialty substance abuse
treatment among study participants based on the receipt of a BI or BI/RT. The study took
advantage of a naturalistic situation where the CT SBIRT Program was being implemented in nine
community health center sites across the state. Admission to specialty substance abuse treatment
was determined by matching study participant identifiers to the CT DMHAS administrative
database of specialty substance abuse treatment.

3.3. Study Locations
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The study locations included nine community health centers (CHCs) across Connecticut who opted
to participate with the Connecticut SBIRT Program, including: 1) Community Health Services in
Hartford; 2) Cornell Scott-Hill Health Center in New Haven; 3) Fair Haven Community Health
Center in New Haven; 4) First Choice Health Center in East Hartford; 5) Greater Danbury
Community Health Center in Danbury; 6) Optimus Health Care in Bridgeport and Stamford; 7)
Southwest Community Health Center in Bridgeport; 8) StayWell Health Center in Waterbury; and
9) United Community Family Services in Norwich. CHCs provide accessible, comprehensive, and
quality health care, including medical, dental, behavioral health, and related services, primarily
serving uninsured, low-income families, and ethnically/racially diverse populations. Prevalence
rates for many health behavior risk factors, including substance use, are highest among uninsured
and Medicaid-eligible populations. The prevalence of substance use disorders among
Connecticut’s current Medicaid-eligible populations in Connecticut is 21.6% compared to a
prevalence rate of 23.2% for uninsured income-eligible individuals (SAMHSA, 2012). Both of the
above rates are substantially higher than the SAMHSA prevalence rate of 8.3% for substance use
disorders among general populations (SAMHSA, 2014). CHCs offer unique opportunities to
identify and intervene early with low income, high-risk individuals whose substance use is
hazardous or harmful. Table 2 provides a summary of patient demographic information for
community health centers participating with CT SBIRT.

Table 2 Patient Demographics for Community Health Centers FY 2012
Community
Center
Community
Health ServicesHartford

Unduplicated
Adults 18+ Served
14,064

%
White
30%

%
Black
52%
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%
Latino/a
34%

Payer Mix
Uninsured: 23%
Medicaid: 59%

Medicare: 5%
Private Insurance: 12%
Cornell-Scott Hill
28,193
35%
31%
34%
Uninsured: 18%
Health CenterMedicaid: 63%
New Haven
Medicare: 8%
Private Insurance: 11%
CT Institute for
3,726
63%
6%
27%
Uninsured: 16%
CommunitiesMedicaid: 35%
Danbury
Medicare: 12%
Private Insurance: 37%
Fair Haven
9,903
12%
12%
60%
Uninsured: 28%
Community
Medicaid: 54%
Health CenterMedicare: 7%
New Haven
Private Insurance: 11%
Generations
15,817
68%
7%
22%
Uninsured: 23%
Family Health
Medicaid: 54%
CenterMedicare: 10%
Willimantic
Private Insurance: 12%
Optimus Health
31,393
69%
26%
57%
Uninsured: 27%
Center-Bridgeport
Medicaid: 55%
& Stamford
Medicare: 6%
Private Insurance: 12%
Staywell Health
13,624
58%
20%
50%
Uninsured: 19%
Center-Waterbury
Medicaid:69%
Medicare: 7%
Private Insurance: 4%
Southwest
13,662
17%
37%
41%
Uninsured: 27%
Community
Medicaid: 57%
Health CenterMedicare: 5%
Bridgeport
Private Insurance: 11%
United
8,780
62%
11%
10%
Uninsured: 14%
Community &
Medicaid: 58%
Family ServicesMedicare: 7%
Norwich
Private Insurance: 18%
TOTALS
138,352
48%
25%
41%
Uninsured: 23%
Medicaid: 58%
Medicare: 7%
Private: 12%
*Retrieved from U.S. HRSA website (https://bphc.hrsa.gov) based on 2012 UDS Data.

3.4. Participant Sample and Eligibility
The study population includes adults, ages 18 and over, who presented at one of the nine
community health centers implementing the CT SBIRT Program between March 1, 2011 and
March 31, 2013 and who screened at moderate-risk or at high-risk on the ASSIST for alcohol
and/or other substances and who were offered a BI or BI/RT. Individuals who screened at low34

risk on the ASSIST were provided feedback by the Health Educators (HEs) on their ASSIST score
and what it represents, in addition to being provided a positive educational message and
encouragement to continue their healthy behaviors. No further action was taken with individuals
who screened at low-risk. Individuals who screened at moderate-risk or at high-risk on the ASSIST
were asked permission to discuss their substance use, and, if the participant was willing, moved
into a BI. Participants in the high-risk group, in addition to receiving a BI, were also referred to
specialty substance abuse treatment (RT) for additional assessment and possible placement in an
appropriate level of care. Admission to specialty substance abuse treatment was determined by
matching study participant identifiers to the CT DMHAS administrative database of specialty
substance abuse treatment.
3.5. Screening, Brief Intervention, and Referral to Treatment (SBIRT) Procedures
Screening Procedure and Assessment. Patients presenting for primary healthcare services at one
of nine participating CHCs in Connecticut received SBIRT services as part of their routine clinical
care from trained Health Educators (HEs). The HEs, introduced by the medical staff or selfintroduced as members of the health treatment team, began the patient interaction by discussing
how lifestyle factors such as alcohol and/or other drug use might impact health. Once rapport was
established, the HE collected general demographic information and screened patients for alcohol
and other substance use utilizing the Alcohol, Smoking, and Substance Involvement Screening
Test (ASSIST) to obtain a risk level of substance use (no risk, low-risk, moderate-risk or highrisk). The ASSIST was developed by the World Health Organization specifically for use in primary
healthcare settings where harmful substance use among patients may go undetected. Validity of
the ASSIST for identifying substance use in individuals who use a number of substances and have
varying degrees of substance use has been demonstrated in a number of multi-site international
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studies (Humeniuk et al., 2007). It was demonstrated that the ASSIST can discriminate between
low-, moderate-, and high-risk substance use across multiple substances, including alcohol,
cannabis, opioid, and cocaine use (Humeniuk et al., 2007). Figure 2 shows the Connecticut SBIRT
Program patient flow based on ASSIST scores.

Figure 2 CT SBIRT Program Study Design—Patient Flow

SBIRT Health Educators Administer the ASSIST
Screening Tool

Patients 18 years
and Older

ASSIST Score:
0-10 on
Alcohol and/or
0-3 for Drugs

Low Risk
No Intervention;
Encouraged to
continue no risk
behaviors

Positive Score:
11-19 on
Alcohol and/or
4-19 for Drugs

Moderate-Risk
Brief
Intervention
(BI) Only

Patients 17 years
and Younger

Positive Score:
20-26 on Alcohol
and/or 20-26 for
Drugs

No Action

Positive Score:
27+ on Alcohol
and/or 27+ for
Drugs

High Moderate-Risk/High-Risk
BI and Referral to Specialty Treatment
(RT)

Analysis of CT SBIRT36
and CT DMHAS Substance Abuse
Treatment Data (Up to 12 months Post-SBIRT) to Match
Patients

The ASSIST assesses severity or risk level from past 3-month use of alcohol and illicit drugs. For
each substance endorsed, questions are asked regarding frequency of use in the previous three (3)
months. Following the administration of the ASSIST, which typically takes 5-10 minutes, separate
risk scores are calculated for alcohol and substance reported, with scores falling in the low-,
moderate-, or high-risk range. For the alcohol-related questions, participants were asked: 1) How
often do you have a drink containing alcohol?; 2) How many drinks containing alcohol do you
have on a typical day when you are drinking?; and 3) How often do you have five (if male)/four
(if female) or more drinks on one occasion? For the other drug-related questions, participants were
asked: 1) In your life, which of the following substances have you ever used (Table 3 below
includes listing of substances included in the tool)?; 2) In the past three months, how often have
you used the substances you mentioned?; 3) In the past 3 months, how often have you had a strong
desire or urge to use?; 4) During the past 3 months, how often has your use led to health, social,
legal, or financial problems? Response choices include Never, Once or Twice, Monthly, Weekly,
or Daily or Almost Every Day; 5) During the past 3 months, how often have you failed to do what
was normally expected of you because of your use? Response choices include Never, Once or
Twice, Monthly, Weekly, or Daily or Almost Every Day; 6) Has a friend or relative or anyone else
ever expressed concern about your use? Response choices include Never, Yes—in the past 3
months, or Yes, but not in the past 3 months; and 7) Have you ever tried and failed to control, cut
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down or stop using? Response choices include Never, Yes—in the past 3 months, or Yes, but not
in the past 3 months. Listing of substances captured on the ASSIST Tool is provided in Table 3.

Table 3 ASSIST Tool Substances List
a.   Tobacco products such as cigarettes, chewing tobacco, cigars, etc.
b.   Alcoholic beverages such as beer, wine, hard liquor, etc.
c.   Marijuana, pot, grass, reefer, weed, ganja, hash, chronic, gangster, joints, blunts, Mary Jane, etc.
d.   Cocaine or Crack, coke, blow, snow, flake, toot, rock, etc.
e.   Prescription stimulants such as Ritalin, Concerta, Adderall, Dexedrine, diet pills, etc.
f.   Methamphetamine, uppers, speed, crystal meth, ice, chalk, glass, fire, crank, etc.
g.   Inhalants or anything you might huff, like glue, correction fluid, gasoline, butane, paint thinner,
lighter fluid, spray paint, poppers, snappers, Rush, Nitrous Oxide, laughing gas, whippets, etc.
h.   Sedatives or sleeping pills such as Diazepam (Valium), Lorazepam (Ativan), Alprazolam (Xanax),
Triazolam, Halcion, Librium, Restoril, Estazolam (ProSom), Rohypnol (roofies, roche, cope),
Serepax, Seconal, pentobarbital sodium (Nembutal), Phenobarbital, mephobarbitol (Mebacut),
GHB (Grievous Bodily Harm, Georgia Home Boy, Liquid X, Liquid Ecstasy), Ketamine (Special
K, Vitamin K), downers, tranquilizers, sedatives, hypnotics, etc.
i.   Hallucinogens/psychedelics, LSD (acid, Boomers, Yellow Sunshine), mushrooms, mescaline, PCP
(Angel Dust, Ozone, Wack, Rocket Fuel), MDMA (Ecstasy, XTC, Adam, X), wet, illy, etc.
j.   Prescription pain medication such as fentanyl, oxycodone, OxyContin, Percocet, hydrocodone,
Vicodin, methadone, buprenorphine, codeine, Darvon, Dilaudid, Demerol, Lortab, Talwin-Nx,
Tylenol-2, -3, -4, morphine, non-prescription methadone, etc.
k.   Heroin, opium, Smack, H, Junk , Skag
l.   Other drug: Something not listed here? Please specify: ____________________________

Scores obtained on the ASSIST determine the type of intervention provided: (1) no intervention,
(2) BI only, and (3) BI plus referral to specialty substance abuse treatment (RT). Individuals
scoring positive on the ASSIST were offered the appropriate level of intervention and/or referral
to specialty substance abuse treatment prior to or immediately following their medical
appointment. Individuals who scored at no-risk on the ASSIST were informed by the Health
Educator (HE) of their screening score, its meaning and were encouraged to continue healthy
behaviors. For individuals who scored at moderate-risk on the ASSIST, HEs provided feedback
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on the screening score and offered an opportunity to receive a BI to encourage cessation of use. If
accepted by the individual, the BI would generally take 10-15 minutes and included assessment of
Stage of Change, establishment of goals with the individual, and a review of strategies for change,
in addition to providing the patient literature on the effects of alcohol and drug use. If requested
by the individual or indicated by risk level, the HE also provided referral to brief treatment and/or
a referral to specialty substance abuse treatment. For individuals who scored at high-risk on the
ASSIST, the HE provided feedback on the screening score, offered an opportunity to receive a BI,
and offered referral to brief treatment and/or to a specialty substance abuse treatment provider.
The BI primarily focus was on increasing insight and awareness regarding substance use and
motivation towards behavioral change. Individuals scoring positive had the choice not to
participate with the offered BI or, in some instances, external barriers may have interfered with
providing the BI, e.g., HE was engaged with another client, medical appointment interfered with
BI session. Table 4 below shows the risk-level scores for alcohol and drugs and the indicated
interventions for each risk level, as specified in the WHO BI Manual (WHO, 2002).

Table 4 ASSIST Screening Risk Scores and Indicated Intervention
Risk Score

Risk Level

Indicated Intervention

ASSIST Alcohol Score 0-11 and/or
ASSIST Drug Score 0-3

Low-Risk

-Feedback on ASSIST
-No Intervention

ASSIST Alcohol Score 11-19 and/or
ASSIST Drug Score 4-19
ASSIST Alcohol Score 20-26 and/or
ASSIST Drug Score 20-26 (Moderate
High-Risk)

Moderate-Risk
Moderate High-Risk/
High-Risk

ASSIST Alcohol Score 27+ and/or
ASSIST Drug Score 27+ (High-Risk)
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-Feedback on ASSIST Score
-Brief Intervention
-Feedback on ASSIST Score
-Brief Intervention
-Referral to Specialty Treatment

Health Educators Training. Health Educators (HEs), employed through the CT SBIRT Program,
were trained and provided supervision through the UCHC SBIRT Training Institute. The UCHC
SBIRT Training Institute evaluated HEs’ application of SBIRT, self-efficacy in providing SBIRT
services, knowledge essential to conducting SBIRT, and other components known to affect
implementation of SBIRT. Ten full time equivalent HE staff were trained and certified in SBIRT
approaches and received ongoing coaching and regular evaluation of their proficiency in
motivational interviewing. HEs underwent extensive training at UCHC’s Training Institute prior
to implementing SBIRT services in the field. Depending on HE experience and background,
training may last as long as a month or be completed within 7-8 days. Once training was completed,
HEs were expected to have a complete understanding of the overall structure and the need for the
services provided by CT SBIRT including: 1) the roles and duties of all members and member
organizations that are part of the CT SBIRT team; 2) the continuum of CT SBIRT services as they
relate to the continuum of substance use; 3) the conditions likely to be encountered in the health
center settings and associated challenges; 4) motivational interviewing theory, key methods and
practiced motivational techniques; 5) the CT SBIRT Program protocols for screening, BI, and
making referrals to specialty substance abuse treatment; 6) the importance of patient
confidentiality and ways in which confidentiality might become an issue in delivering services; 7)
HIPAA regulations and necessary steps for compliance with those regulations; 8) elements of
cultural proficiency and working with ethnically diverse patients; 9) ensuring patient and GPRA
information is processed appropriately; 10) relevant GPRA requirements and the importance of
meeting those requirements; and 11) Relevant ethical requirements and the importance of meeting
the requirements (CT SBIRT Program, 2011). Although the CT SBIRT Program, through the
UCHC SBIRT Training Institute, provided standardized training and technical assistance supports
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to the nine participating CHCs and employed Health Educators, variation in implementation of
SBIRT services across community health centers and Health Educators was possible.

3.6. Data Sources
Administrative data offers a rich resource for understanding individuals with substance use
disorders (Sears, 2010). This study draws on existing administrative datasets from a number of
sources, including: 1) the Connecticut DMHAS DDaP database, which includes a rich set of sociodemographic, diagnostic, and substance abuse treatment utilization data for individuals admitted
to a licensed substance abuse treatment facility in Connecticut, and 2) the Connecticut SBIRT
Program data, which includes the federal Government Performance and Results Act (GPRA) Core
Client Outcome domains in addition to the ASSIST screening scores and SBIRT services provided
to patients. Data collected through GPRA are used to report on the National Outcome Measures
(NOMs) and include the following domains: (1) abstinence from drug use and alcohol abuse, or
decreased mental illness symptomatology; (2) increased or retained employment and school
enrollment; (3) decreased involvement with the criminal justice system; (4) increased stability in
family and living conditions; (5) increased access to services; (6) increased retention in services
for substance abuse treatment or decreased utilization of psychiatric inpatient beds for mental
health treatment; and (7) increased social connectedness to family, friends, co-workers and
classmates (SAMHSA, 1993). The GPRA survey instrument must be collected and reported by all
SAMHSA-funded grant programs. For the SBIRT program, GPRA data is collected and reported
to SAMHSA at intake, and for 10% of the evaluation cohort, at 6-month follow-up. The
Connecticut SBIRT Program data set also includes screening interview responses, and record of
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BIs or BIs/RTs provided for individuals who received SBIRT services at any Connecticut SBIRT
Program intervention site. Summary of data sources is provided in Table 5.

Table 5 Administrative Data Sources
Data
Source
DDaP

Data Held
CT DMHAS

Description of Data
Admission and
Treatment Data for
all Individuals who
were admitted to a
CT-licensed
Substance Abuse
Treatment Program.

Derived Measures
•  
•  
•  
•  
•  

CT SBIRT
Program:
GPRA Data

CT SBIRT
Program:
ASSIST
Data

UCHC

UCHC

Demographic and
GPRA data for all
Individuals Provided
a CT SBIRT Program
service.

•  

ASSIST Scores and
Services Provided
through the CT
SBIRT Program.

•  
•  

•  
•  

3.7. Data on Screened Sample
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Demographics (Age, Gender, Race
/Ethnicity)
Admission Date to Specialty Substance
Abuse Treatment
Discharge Date from Specialty Substance
Abuse Treatment
Admission Lifetime to Specialty Substance
Abuse Treatment
Substance Abuse Diagnosis
Reported alcohol or drug use in the past 30
days
Demographics (Age, Gender,
Race/Ethnicity)
Improvements in domains of abstinence,
alcohol/illicit drug related consequences,
housing, and employment.
ASSIST screening scores
Services Offered: (1) no intervention, (2)
brief intervention (BI) only, or (3) BI plus
referral to specialty treatment (RT).

Over the targeted study period, March 1, 2011 through March 31, 2013, 28,637 unduplicated
patients were screened utilizing the ASSIST screening instrument at the community health centers
participating with the Connecticut SBIRT Program. Table 6 shows the demographic characteristics
of the screened, unduplicated sample population. Sixty-three percent (63.2%) of the sample
population were female. The age range of the study population was dispersed by the following age
groups: 9.3% aged 18-24; 19.5% aged 24-35; 19.7% aged 35-44; 23.4% aged 45-54; and 28.1%
aged 55 years and older. The study sample was comprised of 44.7% non-Hispanic Whites, 46.3%
Hispanics, and 26.1% Blacks. Based on the ASSIST scores, 1,442 (5%) of the population scored
at-risk for alcohol; 2,110 (7.4%) for cannabis; 713 (2.5%) for heroin; 985 (3.3%) for cocaine; and
289 (1%) for prescription opiates.

Table 6 Characteristics of Unduplicated Screened Sample
N=28,637

Demographic Variables

Frequency

Percentage

GENDER

Male
Female
Transgender

10,518
18,102
13

36.7%
63.2%
00.0%

18-24
25-34
35-44
45-54
55+

2,650
5,592
5,639
6,692
8,058

9.3%
19.5%
19.7%
23.4%
28.1%

13,266
15,106
265

46.3%
52.7%
.9%

7,707
12,801
709
91
3,836

26.9%
44.7%
2.5%
.3%
13.4%

_______
AGE

ETHNICITY—HISPANIC/LATINO
Yes
No
Missing/Refused
RACE

Black
White
Asian
American Indian
Missing/Refused

SUBSTANCE USE SEVERITY MEASURES
ASSIST Alcohol Scores
Frequency
0-10
27,554

Percentage
96.7%
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11-19
20+

586
553

.02%
.03%

Based on the ASSIST Score, 1,442 or 5% of Sample Population was at-risk for Alcohol
ASSIST Cannabis Scores
Frequency
Percentage
0-3
26,423
92.6%
4-19
1,894
6.7%
20+
216
.6%
Based on the ASSIST Score, 2,110 or 7.3% of the Sample Population was at-risk for Cannabis
ASSIST Heroin Scores
Frequency
Percentage
0-3
27,829
97.5%
4-19
613
2.1%
20+
100
.4%
Based on the ASSIST Score, 713 or 2.5% of Sample Population was at-risk for Heroin

ASSIST Cocaine Scores
0-3
4-19
20+

Frequency
27,584
848
110

Percentage
96.6%
.3%
.00%

Based on the ASSIST Score, 985 or 3.3% of Sample Population was at-risk for Cocaine
ASSIST RX Opiates Scores
0-3
4-19
20+

Frequency
28,253
259
30

Percentage
99%
.9%
.00%

Based on the ASSIST Score, 289 or 1% of Sample Population was at-risk for RX Opiates

3.8. Eligible Study Participants
Eligible study participants were defined as adults (18 years and older) who screened at moderaterisk or at high-risk for alcohol and/or other substances utilizing the ASSIST screening instrument
at one of the CHCs participating with the Connecticut SBIRT Program between March 1, 2011
and March 31, 2013. CT SBIRT Program participants were then matched to the State of
Connecticut DMHAS specialty substance abuse treatment database to determine whether they
entered treatment after their SBIRT encounter up to one-year post-SBIRT intervention. The
Connecticut DMHAS database includes admission and discharge data for all licensed substance
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abuse treatment programs, including substance abuse residential detoxification, long-term
rehabilitation, intensive and intermediate residential, medication assisted treatment, including
methadone maintenance, outpatient, and partial hospitalization. Of the 28,637 screened study
sample, 24,600 participants screened at low risk on the ASSIST and were excluded. Threethousand nine-hundred and forty-eight (3,948) participants screened at moderate- to high-risk on
the ASSIST. Of the 3,948 participants, 3,931 were deemed eligible study participants, with 17
participants being excluded from the analyses due to missing data. The final eligible study sample
included 3,931 participants of which 3,235 screened at moderate-risk and were offered a BI and
696 screened at high-risk and were offered a BI/RT. Approximately sixty-one percent (61%) of
the eligible study participants were male. The eligible study sample was comprised of 31% nonHispanic Whites, 36% Hispanics, and 29% Blacks. The minimum age of the study population was
18 years and the maximum age was 79 years, with study population having a mean age of 41.
Approximately 14% (n=541) of eligible study sample has received specialty substance abuse
treatment up to one-year post-SBIRT intervention.

Table 7 Characteristics of Unduplicated, Eligible Study Sample (N=3,931)
Demographic Variables
GENDER
Male
Female
RACE
Black
White
Other
ETHNICITY
Yes Hispanic
POST-SBIRT SPECIALITY TX
Yes
No

Frequency

Percentage

2,407
1,524

61%
39%

1,213
1,161
132

31%
29%
.03%

1,425

36%

541
3,396

14%
86%
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AGE

Minimum Age: 18.09
Maximum Age: 78.56
Mean Age: 41.38

Figure 3, below, provides a flow diagram for the eligible study participants.

Figure 3 Flow Diagram for Study Participants
28,637 Individuals Screened

24,600 Excluded
•   Screened No/Low Risk

3,948 Screened Moderate/High Risk

3,240 Screened at Moderate-Risk &
Offered Brief Intervention (BI)
697 Screened at High-Risk & Offered
BI and Referral to Specialty SA TX
(RT)
17 Excluded Missing Data

3,931 Eligible Study Participants
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3.9. Data Analyses
This study was designed to test the odds of admission to specialty substance abuse treatment based
on severity of substance involvement and the receipt of BI or BI/RT interventions. A secondary
exploratory aim was to assess differential effects in admission to specialty treatment based on age,
gender, race/ethnicity, ASSIST severity, alcohol and/or other substance reported, pre-SBIRT
mental health treatment, and pre-SBIRT specialty substance abuse treatment among study
participants based on the receipt of a BI or BI/RT. Admission to specialty substance abuse
treatment was the measured dependent variable. The independent variables, extracted from the
Connecticut DMHAS, the Connecticut SBIRT GPRA data, and the Connecticut SBIRT Program,
including ASSIST severity scores, demographic data, specifically age, gender, race/ethnicity,
previous admission to specialty substance abuse treatment, and reported substance used. Outcome
measures were drawn from the CT SBIRT Program database, including GPRA and ASSIST data,
and from the DMHAS DDaP administrative service records. Matched substance abuse treatment
data from the DMHAS DDaP data repository was used to determine association between SBIRT
and admissions to specialty substance abuse treatment. DMHAS, through a patient matching
algorithm based on name, age, residence, gender, and race/ethnicity, used the CT SBIRT Program
data to match individuals who entered specialty substance abuse treatment pre-SBIRT within 365
days post-SBIRT service as captured in the CT SBIRT Program database. Admission to specialty
substance abuse treatment was defined as admission to treatment, (1=yes, 0=no), and included
admission data to any licensed specialty substance abuse treatment modality, i.e., residential
detoxification, long-term rehabilitation, intensive and intermediate residential, medication assisted
treatment including methadone maintenance, outpatient, and partial hospitalization treatment.

47

DMHAS provided a de-identified data set of matched records which were used to conduct the
analyses identified below.

3.10. Statistical Analysis
Chi-square tests were used to explore differences of the screening sample, overall sample
characteristics, and to investigate post-SBIRT service admissions to specialty substance abuse
treatment and demographics and characteristics of patients, including ASSIST severity data,
demographic data, specifically age, gender, race/ethnicity, previous mental health treatment,
previous admission to specialty substance abuse treatment, and reported substance used. Crosstabulations were used to describe rates across demographic subgroups. Multilevel logistic
regression analyses were conducted to compare the odds of post-SBIRT admission to specialty
substance abuse treatment for study participants who received a BI or BI/RT and examine
interactions with a number of patient characteristics, including age, gender, race/ethnicity, prior
lifetime history of specialty substance abuse treatment, prior history of mental health treatment,
and ASSIST severity score. The multilevel logistic regression analyses allowed for a “stepped”
approach in which each of the above patient characteristics were added one-by-one to examine the
effect of independent measures on post-SBIRT admission to specialty substance abuse treatment.
Type 1 error rate was set at a=.05 for hypothesized effects. Interpretation of findings factored in
clinical relevance, in addition to statistical significance. Output and data analyses for this study
were generated utilizing SPSSÒ Statistics software, Version 22.0 (IBM SPSS Statistics, 2013).

3.11. Human Subjects
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This study was approved by both UCHC and the Connecticut DMHAS Institutional Review
Boards (IRBs). IRB approval for data analysis and reporting was in effect while study participants
were enrolled in the study for the March 2011-March 2013 period.

CHAPTER 4: RESULTS
4.1. Overview
Chapter 4 presents the findings based on the analyses methods and procedures described in Chapter
3.

4.2. Study Hypothesis
The study hypothesis was based on the assumption that study participants who screened at highrisk on the ASSIST for substance use and were offered a BI/RT would be more likely to engage
in specialty substance abuse treatment within a year post-SBIRT intervention compared to those
who screened at moderate-risk on the ASSIST and received a BI only Study participants who
screened at high-risk and who were offered BI/RT, which facilitates engagement into specialty
substance abuse treatment, would present to specialty substance abuse treatment at higher rates
than study participants who screened at moderate-risk on the ASSIST.
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Multilevel logistic regression analyses were conducted to examine the odds of admissions to
specialty substance abuse treatment based on study participants’ receipt of a BI or BI/RT as part
of health center SBIRT services within the previous year. Of the 3,937 study participants included
in the analyses, or 12.4% of the total CT SBIRT Program population, 3,240 study participants
scored at moderate-risk on the ASSIST for alcohol and/or other substances and were offered a BI.
The remaining 697 study participants scored at high-risk on the ASSIST for alcohol and/or other
substances and were offered a BI and referral to specialty treatment (RT). Of the total population
offered a BI or BI/RT, 541 study participants had a post-SBIRT admission to specialty substance
abuse treatment up to 1 year post-SBIRT. Of particular note is the significant effect found for study
participants who screened at high-risk on the ASSIST for alcohol and/or other substances and who
were offered a BI/RT and admission to post-SBIRT specialty treatment. The odds of the BI/RT
study population having a post-SBIRT admission to specialty treatment was 2.78 times greater
than the odds of study participants who screened at moderate-risk and who were offered a BI only
[OR= 2.78; 95% CI 2.27, 3.40]. In the second model, which in addition to BI or BI/RT also
included age, gender (male), and race/ethnicity, we found an increase in the odds of the BI/RT
study population having a post-SBIRT admission to specialty treatment [OR= 2.82; 95% CI 2.30,
3.46]. In the second model, BI/RT study participants had 2.82 greater odds of having a post-SBIRT
admission to specialty treatment than BI only study participants. In the third model, which in
addition to BI or BI/RT included age, gender (male), race/ethnicity, prior history of mental health
treatment, and prior history of substance abuse treatment, we found a decrease in odds of the BI/RT
study population having post-SBIRT admission to specialty treatment [OR= 2.31; 95% CI 1.86,
2.88]. In the third model, BI/RT study participants had 2.31 greater odds of having an admission
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to specialty treatment than study participants who were only offered a BI. The final model, in
addition to BI or BI/RT, included age, gender (male), race/ethnicity, prior history of mental health
treatment, prior history of substance abuse treatment, and ASSIST severity scores. For this model,
the odds of the BI/RT study population having a post-SBIRT admission to specialty treatment
reduced to 1.67; therefore BI/RT study participants had 1.67 greater odds of admissions to
specialty treatment post-SBIRT than study participants who were only offered a BI [OR= 1.67;
95% CI 1.19, 2.34]. In summary, odds of post-SBIRT admission to specialty treatment were
between 2.88 and 1.67 for the BI/RT study participants than for the BI only study participants.

Table 8 Predicting Odds of Admission to Specialty Treatment (n = 3,937)

Characteristics:
BI/RT versus BI

Model 1
(Unadjusted)
OR 95%CI

Model 2
(Adjusted)
OR 95%CI

Model 3
(Adjusted)
OR 95%CI

2.78 (2.27, 3.40)

2.82 (2.30, 3.46)

2.31 (1.86, 2.88)

Model 4
(Adjusted)
OR 95%CI
1.67 (1.19, 2.34)

Demographics:
Age

1.00 (0.99, 1.00)

0.99 (0.98, 0.99)

0.98 (0.97, 0.99)

Gender (Male)

0.85 (0.70, 1.03)

0.92 (0.75, 1.14)

0.90 (0.72, 1.12)

Ethnicity-Hispanic

0.69 (0.42, 1.14)

1.00 (0.59, 1.73)

1.12 (0.64, 1.98)

Race-Black

0.51 (0.41, 0.64)

0.70 (0.55, 0.89)

0.70 (0.55, 0.90)

Race-White

0.56 (0.44, 0.70)

0.68 (0.53, 0.88)

0.77 (0.60, 1.00)

0.12 (0.09, 0.15)

0.14 (0.10, 0.18)

0.55 (0.44, 0.67)

0.58 (0.47, 0.72)

Prior Treatment History:
Prior SA Treatment
Prior MH Treatment
ASSIST Severity Score:
Alcohol Score

1.01 (0.99, 1.02)

Cannabis Score

0.97 (0.96, 0.99)

Cocaine Score

1.03 (1.02, 1.05)

Opiate Score

1.05 (1.03, 1.07)
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4.3. Secondary Exploratory Aim
The secondary exploratory aim was to explore differential effects in admission to specialty
treatment based on age, gender, race/ethnicity, ASSIST severity, alcohol and/or other substance
reported, pre-SBIRT mental health treatment, and pre-SBIRT specialty substance abuse treatment
among study participants based on the receipt of a BI or BI/RT. Multilevel logistic regression
analyses were conducted to predict odds of post-SBIRT admissions to specialty substance abuse
treatment. The multilevel regression allowed for a “stepped” regression by adding study participant
characteristics one-by-one to examine the effects of independent measures on post-SBIRT
admission to specialty substance abuse treatment. The stepped regression models were designed
to identify characteristics that account for treatment engagement among study participants that
present for specialty substance abuse treatment post-SBIRT. We tested a five level multilevel
logistic regression model. Independent variables were sequentially added to BI and BI/RT in the
following five models: Model 1: BI, BI/RT and Age, Model 2: BI, BI/RT and Gender, Model 3:
BI, BI/RT and Race/Ethnicity, Model 4: BI, BI/RT and Prior Mental Health Treatment, and Model
5: BI, BI/RT and Prior Specialty Substance Abuse Treatment.

Significant effect was found for study participants who screened at high-risk on the ASSIST for
alcohol and/or other substances who were offered a BI/RT and who had a pre-SBIRT admission
to specialty treatment. The odds of the BI/RT study participants with prior substance abuse
treatment having a post-SBIRT admission to specialty treatment was 4.75 times greater than the
odds of study participants who did not have prior substance abuse treatment admission [OR= 4.75;
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95% CI 2.63, 8.57]. No significant effects were predicted for BI or BI/RT and age, gender,
race/ethnicity or prior mental health treatment, where each characteristic was examined one-byone to measure the independent effects on post-SBIRT admission to specialty substance abuse
treatment.

Table 9 Predicting Differential Effects of Independent Variables on Admission to Specialty
Treatment (n = 3,937)
Multilevel Logistic Regression Stepped Models

OR 95%CI

BI/RT, Age

1.01 (0.98, 1.03)

BI/BT, Gender (Male)

1.42 (0.87, 2.31)

BI/RT, Ethnicity-Hispanic

2.81 (0.83, 9.56)

BI/RT, Race-Black

1.14 (0.65, 2.00)

BI/RT, Race-White

0.84 (0.46, 1.53)

BI/RT, Prior MH Treatment

1.39 (0.88, 2.20)

BI/RT, Prior SA Treatment

4.75 (2.63, 8.57)

The cross-tabulation output, presented in Table 10, reflects that 11.3% (n=31) of study participants
with no prior SBIRT admission to specialty substance abuse treatment that were offered BI/RT,
therefore scored at high-risk for alcohol and/or other substances on the ASSIST, had an admission
to specialty substance abuse treatment within one year of the SBIRT intervention. In comparison,
1.7% (n=30) of study participants with no prior SBIRT admission to specialty substance abuse
treatment who scored at moderate-risk for alcohol and/or other substances on the ASSIST, had an
53

admission to specialty substance abuse treatment within one year of the SBIRT intervention. For
study participants who were offered BI/RT and who had prior to SBIRT admission to specialty
treatment, 35.2% (n=149) had an admission to specialty substance abuse treatment within one year
of the SBIRT intervention. In comparison, 22.6% (n=331) of study participants that were offered
a BI, therefore screened at moderate-risk on the ASSIST, had an admission to specialty substance
abuse treatment within one year of the SBIRT intervention. As hypothesized, study participants
who were offered a BI/RT presented to specialty substance abuse treatment post-SBIRT at a higher
frequency than participants who we only offered a BI, with overall 25.8% (n=180) of the
population that was offered BI/RT having an admission to specialty substance abuse treatment
within one year of the SBIRT intervention in comparison to 11.1% (n=361) of study participants
that were offered a BI having an admission to specialty substance abuse treatment within one year
of the SBIRT intervention.

Table 10 Cross Tabulation of Pre- and Post-SBIRT Specialty Treatment for Study
Participants Offered BI or BI/RT

YES
Prior & Post-SBIRT
POST-SBIRT
Specialty TX
TX
No Prior
BI/RT N
31
TX
% within BI/RT Participants
11.3%
BI
N
30
% within BI Participants
1.7%
TOTAL N
61
% within BI or BI/RT
3.0%
Participants
Yes Prior BI/RT N
149
TX
% within BI/RT Participants
35.2%
BI
N
331
% within BI Participants
22.6%
TOTAL N
480
% within BI or BI/RT
25.4%
Participants
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NO
POST-SBIRT
TX
243
88.7%
1744
98.3%
1744
97.0%

TOTAL
274
100%
1774
100%
1774
100%

274
64.8%
1135
77.4%
1409
74.6%

423
100%
1466
100%
1889
100%

Total

BI/RT

N
% within BI/RT Participants
BI
N
% within BI Participants
TOTAL N
% within BI or BI/RT
Participants

180
25.8%
361
11.1%
541
13.7%

517
74.2%
2879
88.9%
3396
86.3%

697
100.0%
3240
100%
3937
100%

Chi-square analysis was conducted to further examine the significance of the interactions of prior
substance abuse treatment and post-SBIRT admission to specialty treatment for study participants
who were offered a BI/RT. Results of the Chi-Square Test, Table 11 below, show statistically
significant interactions for study participants offered BI/RT with no prior-SBIRT admission to
specialty substance abuse treatment [Chi-Square=76.05, p< 0.000] and for study participants
offered BI/RT with prior-SBIRT admission to specialty treatment [Chi-Square=27.70, p< 0.000].

Table 11 Specialty Treatment Pre-SBIRT vs. Post-SBIRT

No
Prior-SBIRT
Specialty TX
Yes
Prior-SBIRT
Specialty TX
Total

Value
76.051

df
1

Asymptotic Significance
(2-sided)
.000

27.699

1

.000

104.330

1

.000

In summary, a significant effect was found for study participants who screened at high-risk on the
ASSIST for alcohol and/or other substances who were offered a BI/RT and who had a pre-SBIRT
admission to specialty treatment. The odds ratio, presented in Table 12, shows that overall study
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participants who were offered BI/RT were 2.78 times more likely to have a post-SBIRT admission
to specialty treatment if they had a pre-SBIRT admission to specialty treatment.

Table 12 Specialty Treatment Pre-SBIRT vs. Post-SBIRT Odds Ratio
Odds Ratio for
NO Prior-SBIRT
Specialty TX

YES PriorSBIRT
Specialty TX

TOTAL

Value

Odds Ratio for BI/RT

7.416

95% Confidence Interval
Lower
Upper
4.411
12.469

YES Post-SBIRT Specialty TX

6.690

4.117

10.872

NO Post-SBIRT Specialty TX

.902

.864

.941

N of Study Participants
Odds Ratio for BI/RT

2048
1.865

1.476

2.356

YES Post-SBIRT Specialty TX

1.560

1.329

1.831

NO Post-SBIRT Specialty TX

.837

.776

.902

N of Study Participants
Odds Ratio for BI/RT

1889
2.777

2.269

3.398

YES Post-SBIRT Specialty TX

2.318

1.977

2.717

NO Post-SBIRT Specialty TX

.835

.798

.874

No of Study Participants

3937

Differentials in post-SBIRT admissions to specialty substance abuse treatment were explored by
comparing community health centers with on-site availability of specialty substance abuse
treatment to community health centers without on-site availability of specialty treatment (Table 13
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below). The results indicated no statistically significant association between post-SBIRT
admissions to specialty substance abuse treatment for community health centers with on-site
availability of specialty substance abuse treatment in comparison to community health centers
without on-site availability of specialty treatment. This is contrary to the original assumption that
community health centers with on-site availability of specialty treatment would have greater
success in engaging study participants in post-SBIRT specialty treatment.

Table 13 Community Health Centers with On-Site Specialty Treatment
ASSIST
SCREEN
ASSIST
POS & NO SCREEN POS
TX OR
& POSTPRESBIRT
CHC with On-Site Specialty SA Treatment
SBIRT TX
TX
TOTAL
0
Count
2073
329
2402
% within On-Site Specialty TX
86.3%
13.7%
100.0%
% within FOR BI/RT, NOPOST V. POST
60.9%
59.3%
60.7%
1
Count
1332
226
1558
% within On-Site Specialty TX
85.5%
14.5%
100.0%
% within FOR BI/RT, NOPOST V. POST
39.1%
40.7%
39.3%
Total
Count
3405
555
3960
% within On-Site Specialty TX
86.0%
14.0%
100.0%
% within FOR BI/RT, NOPOST V. POST
100.0%
100.0%
100.0%
Exact
Asymptotic Significance
Exact Sig.
Sig.
Chi-Square Tests
Value
Df
(2-sided)
(2-sided)
(1-sided)
Chi-Square
.513a
1
.474
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 218.36.
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CHAPTER 5: DISCUSSION
5.1. Overview
A discussion of the main findings for the study hypothesis, in addition to limitations and strengths
of the dissertation study, is provided. This is followed by the implications that this dissertation
study may have on the future of brief intervention (BI) programs, policies, and ongoing research.
This dissertation study was designed to test the odds of admission to specialty substance abuse
treatment based on severity of substance involvement and the receipt of BI or BI/RT
interventions. A secondary aim was to assess differential effects in admission to specialty
treatment based on age, gender, race/ethnicity, ASSIST severity, alcohol and/or other substance
reported, pre-SBIRT mental health treatment, and pre-SBIRT specialty substance abuse treatment
among study participants based on the receipt of a BI or BI/RT.
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5.2. Substance Abuse, SBIRT & Specialty Treatment
As noted in the Introduction, substance abuse is a major public health burden, accounting for
significant social, physical, and health problems and resulting in considerable health care costs.
Research shows that early engagement of substance-dependent individuals in treatment results in
better outcomes (Timko et al. 1999; Moos & Moos 2003), highlighting the significance of
identifying substance use/abuse issues early via universal screening and intervening with clinically
indicated interventions (e.g., motivationally based brief interventions and/or referral to specialty
treatment). BIs, as a component of SBIRT, are evidence-based procedures that provide immediate
attention to individuals who screen at moderate-risk and high-risk for alcohol and/or other
substance use behaviors. BIs raise individuals’ awareness of substance use and its consequences
and motivate them towards positive behavior change. For individuals at-risk of developing a
serious problem with alcohol and/or substance misuse, the identification of early warning signs
can be enough to change risky drinking or other substance use habits. For others, BIs may be
important first steps toward treatment of and recovery from addiction. Given the vast population
who experience risky alcohol and/or substance use, BIs could have significant public health
implications and positively impact a broad population.

The primary aim of this study was to test the odds of admission to specialty substance abuse
treatment based on severity of substance involvement and the receipt of BI or BI/RT
interventions. The study hypothesis was based on the assumption that study participants who
screened at high-risk on the ASSIST for substance use and were offered a BI/RT would be more
likely to engage in specialty substance abuse treatment within a year post-SBIRT intervention
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compared to those who screened at moderate-risk on the ASSIST and received a BI only. Study
participants who screened at high-risk and who were offered BI/RT, which facilitates engagement
into specialty substance abuse treatment, would present to specialty substance abuse treatment at
higher rates than study participants who screened at moderate-risk on the ASSIST. The secondary
exploratory aim was to explore differential effects in admission to specialty treatment based on
age, gender, race/ethnicity, ASSIST severity, alcohol and/or other substance reported, pre-SBIRT
mental health treatment, and pre-SBIRT specialty substance abuse treatment among study
participants based on the receipt of a BI or BI/RT. Specialty substance abuse treatment was defined
as admission to a licensed substance abuse treatment program within 365 days (one year) postSBIRT intervention as captured by the Connecticut DMHAS administrative substance abuse
treatment database.
5.3. Study Hypothesis
The study hypothesis was based on the assumption that study participants who screened at highrisk on the ASSIST for substance use and were offered a BI/RT would be more likely to engage
in specialty substance abuse treatment within a year post-SBIRT intervention compared to those
who screened at moderate-risk on the ASSIST and received a BI only. There is evidence that BIs
are effective with at-risk and hazardous substance users, and emerging evidence suggests that BIs
can be used to motivate individuals to seek specialized substance abuse treatment (Bien et al.,
1993). To meet this purpose the following study question was posed:

1)   Did study participants who screened at high-risk on the ASSIST for alcohol and/or other
substances and who were offered a BI/RT, have an increased probability of admission to
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specialty substance abuse treatment within the following year (post-SBIRT) compared to
study participants who screened at moderate-risk and who were offered BI only?

The effects of BI or BI/RT may be confounded by addiction severity as captured by the ASSIST.
Therefore we cannot imply that BI/RT was responsible for increased admission to specialty
treatment when only study participants who screened at high-risk on the ASSIST were offered
BI/RT. The severity of substance use was used to assign BI (at moderate-risk) or BI/RT (at highrisk), which may account for the possible effect of BI vs. BI/RT on specialty treatment admission.
This study attempted to reduce the impact of this effect by using multilevel logistic regression
analyses, which allowed for a “stepped” approach in which each patient characteristic was added
one-by-one to examine the effect of independent measures on post-SBIRT admission to specialty
substance abuse treatment. This study also analyzed the Global ASSIST severity score, which took
into account all symptoms across all reported alcohol and other substances. The odds ratio
remained significant, suggesting that the type of intervention (BI or BI/RT) may have contributed
to specialty treatment admission beyond the ASSIST severity score alone. Furthermore, analyses
were also conducted where the BI and BI/RT variables were added last, after the other
demographic variables were added. After controlling for demographics, prior mental health and
substance abuse treatment, and Global ASSIST severity, the BI/RT still made an independent,
significant contribution.

Thus, as hypothesized, study participants offered BI/RT were more likely to engage in specialty
treatment than study participants who were offered BI, after controlling for severity of substance
involvement. The odds of the BI/RT study having a post-SBIRT admission to specialty treatment
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was 2.78 times greater than the odds of study participants who screened at moderate-risk and who
were offered a BI only population [OR= 2.78; 95% CI 2.27, 3.40]. When factoring age, gender
(male), race/ethnicity, prior history of mental health treatment, prior history of substance abuse
treatment, and ASSIST severity scores, the odds of the BI/RT study participants having a postSBIRT admission to specialty treatment was between 1.67 and 2.88 times higher than for the BI
only study participants. These findings indicate that BI/RT, as a component of the SBIRT model,
could potentially impact admissions to specialty substance abuse treatment post-SBIRT
intervention more significantly than BI alone. It is also important to note that BI alone also had a
positive impact on admissions to specialty substance abuse treatment. Study participants that
screened at high-risk on the ASSIST for alcohol and/or other substances had a higher rate (29%)
of post-SBIRT admissions to specialty treatment as compared to study participants (11.4%) who
screened at moderate-risk on the ASSIST for alcohol and/or other substances. It seems logical that
study participants screening high-risk on the ASSIST would be an important moderator for
admission to specialty treatment.

In other studies, BIs have been found to increase the percent of individuals who show up for their
first specialty treatment appointment to range from 5% among controls to 50 to 65% among those
receiving BIs, with as many as 50% of individuals reporting that they continue to be involved in
some kind of substance abuse treatment (Bernstein et al., 1997; D’Onofrio et al., 1998; Dunn and
Ries, 1997). Analysis conducted by Bien et al., (1993) concluded that BIs enhanced the motivation
of treatment-seeking problem drinkers to enter and remain in outpatient or residential alcohol
treatment compared with individuals not receiving such attention. Results from the Krupski et al.,
(2010) study also indicated that patients who received a BI were significantly more likely to enter
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specialized treatment in the subsequent year compared to similar patients who did not receive a
BI. Patients who were provided a referral to treatment in addition to the BI also were associated
with a substantially higher likelihood of subsequent specialty treatment. However, a meta-analysis
conducted by Glass et al., (2015) found no evidence that BIs for alcohol were effective in
increasing the utilization of specialty alcohol treatment, suggesting that the BI and referral to
treatment component of SBIRT may not adequately link patients who need specialty treatment to
those services. The Glass et al. study included only alcohol-related interventions and settings of
the randomized controlled trials varied, including two that were delivered in medical inpatient
units, three in general healthcare settings, eight in emergency departments, and the remaining
studies were conducted outside of the United States. A study by Longabaugh et al., (2010) found
that a booster session, defined as a ten-minute follow-up call approximately one week after the
initial intervention following BI or BI/RT, enhanced the effect of the BI and patient engagement
in specialty treatment. Dissertation study findings indicate that BI/RT within the SBIRT model
more significantly impacts admissions to specialty substance abuse treatment post-SBIRT
intervention than BI alone. It is also important to note that BI alone impacted admissions to
specialty substance abuse treatment.

5.4. Secondary Exploratory Aim
The secondary aim was to explore differential effects in admission to specialty treatment based on
age, gender, race/ethnicity, ASSIST severity, alcohol and/or other substance reported, pre-SBIRT
mental health treatment, and pre-SBIRT specialty substance abuse treatment among study
participants based on the receipt of a BI or BI/RT. Multilevel logistic regression analyses were
conducted to compare the odds of post-SBIRT admission to specialty substance abuse treatment
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for study participants who received a BI or BI/RT and examine interactions with a number of
patient characteristics, including age, gender, race/ethnicity, prior lifetime history of specialty
substance abuse treatment, prior history of mental health treatment, and ASSIST severity score.
The multilevel logistic regression analyses used a “stepped” approach in which each of the above
patient characteristics were added one-by-one to examine the effect of independent measures on
post-SBIRT admission to specialty substance abuse treatment.

Multilevel logistic regression analyses were conducted to predict the effects of multiple variables
on admission to specialty substance abuse treatment post-SBIRT. The multilevel regression
allowed for a “stepped” regression by adding patient characteristics one-by-one to examine the
effects of independent measures on post-SBIRT admission to specialty substance abuse treatment.
No statistically significant relationship was found with age, gender, race or ethnicity or prior
mental health treatment. A statistically significant association was found with study participants
who had pre-SBIRT admission to specialty treatment. Study participants who screened at highrisk on the ASSIST and were offered BI/RT and who had pre-SBIRT admissions to specialty
treatment were 2.78 times more likely to have a post-SBIRT admission to specialty treatment than
study participants with moderate risk who were offered a BI only. Results indicate that study
participants who were offered a BI/RT were significantly more likely to enter into specialty
substance abuse treatment in the subsequent year compared to study participants who were only
offered a BI. The strongest association between study participants who were offered a BI/RT and
post-SBIRT admission to specialty treatment was prior SBIRT admission to specialty treatment.
This may suggest that participants with prior treatment who receive BI/RT may be more willing
to re-engage with specialty treatment because of their prior history of addiction/dependence or
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their familiarity with accessing specialty treatment. Although a history of prior SBIRT admission
to specialty substance abuse treatment was associated with higher likelihood of post-SBIRT
admission to specialty substance abuse treatment, BI/RT also had an impact for those with no prior
specialty substance abuse treatment. Therefore providing BI/RT was associated with higher
likelihood of post-SBIRT admission to specialty treatment.

5.5. Strengths and Limitations of Dissertation Study
This dissertation study included several strengths and weaknesses. Strengths include: 1) RealWorld Implementation: The dissertation study took advantage of the implementation of the
Connecticut SBIRT Program, where SBIRT was implemented across nine community health
centers across the state; and 2) Analysis of Administrative Specialty Treatment Dataset: The study
had the ability to match the SBIRT screened sample to the Connecticut DMHAS administrative
specialty substance abuse treatment dataset, including matching study participants pre-SBIRT
(historical data up to 7 years pre-SBIRT) or up to one year post-SBIRT. The administrative
specialty treatment dataset provided rich patient level information, including socio-economic
characteristics, confirmation of substance abuse diagnosis, and utilization of specialty treatment,
that were matched with the ASSIST and CT SBIRT Program data. Linkage of the SBIRT dataset
with the DMHAS dataset provided the first population level evaluation of the relationship between
SBIRT screening in primary care and subsequent admission to treatment, as documented in the
records of a statewide primary care screening program and in the admission records to a statewide
treatment service monitoring system.
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There are important study limitations that should be noted, including: 1) Non-Randomized Study
Participants: Study participants were not randomized for this study. Thus, study participants may
have been subject to selection bias, although controls for various possible confounders were
included in the statistical analyses. 2) Generalization: Study participants were from community
health centers across Connecticut which serve primarily low-income populations with significant
health issues and greater likelihood of untreated substance use disorders. These individuals are
primarily publically insured (i.e., Medicaid, Medicare), uninsured, and/or underserved from
Connecticut’s urban hubs often with higher rates of substance misuse. It is unclear whether study
results would generalize to other populations or healthcare settings. 3) Non-Research Data: There
are concerns associated with the use of service/administrative data which may not include all
measurements of interest. 4) Variations across Community Health Center Sites: Although all
SBIRT staff were trained and received supervision on the SBIRT model from the University of
Connecticut Health Center SBIRT Training Institute, there may have been differences in
implementation procedures across the various health center study sites. 5) SBIRT Intervention
Fidelity: Although all SBIRT staff were trained and received supervision on the SBIRT model
from the University of Connecticut Health Center SBIRT Training Institute, variations of on-site
supervision for SBIRT services varied per community health center location. Furthermore, the
quality of health educators may have also varied by location, which may have resulted in varying
quality of BI provided and referrals to treatment directly impacting who presented to specialty
treatment and who did not. 5. Self-Report: The self-report ASSIST data is also a limitation to the
study dissertation findings. While the ability to match the SBIRT screened sample to the
Connecticut DMHAS administrative specialty substance abuse treatment data set was helpful, this
study still depends on individual responses to the ASSIST screening questions to determine
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substance use severity and intervention protocol. Individuals who underreported alcohol and/or
substance usage, as well as their substance use and severity symptoms may have been
misclassified.
  

5.6. Public Health Implications
Data from the NSDUH reflects that approximately 20.2 million Americans who were classified as
needing treatment did not receive treatment at a specialty facility (SAMHSA, 2014). There are a
number of internal and external barriers that prevent individuals from seeking, entering, and
remaining in specialty treatment, including guilt, stigma, shame, lack of access to treatment
services, and lack of knowledge regarding treatment availability.

BIs potentially offer

opportunities to address some barriers to specialty treatment by engaging non-treatment seeking
individuals through motivationally based interventions that facilitate entry to specialty treatment.
Further exploration of BI’s potential to engage non-treatment seeking individuals to specialty
treatment is warranted, including further exploration of potential increased significance of
BIs/RTs. Of study participants who screened at moderate-risk on the ASSIST for alcohol and/or
other substances and who were offered a BI, 80.4% had no post-SBIRT admission to specialty
treatment. Of study participants who screened at high-risk on the ASSIST for alcohol and/or other
substances and who were offered BI/RT, 59.9% had no post-SBIRT admission to specialty
treatment. While 40% of study participants who screened at high-risk were admitted to specialty
treatment within one year of being screened, this does offer opportunities to increase engagement
and referral to treatment targeting the 60% who did not present to treatment. This exceeds the
significant gap in treatment seen nationally, where of the estimated 22.7 million Americans who
were classified as needing treatment, only about 2.5 million people (10 percent) received treatment
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at a specialty substance abuse treatment facility (SAMHSA, 2014). The potential for BIs, as a
component of SBIRT, to identify, intervene, and motivate individuals at-risk for alcohol and/or
other substances to access specialty treatment could have a significant impact on healthcare given
current trends of alcohol and/or other substance abuse in the United States. The findings of this
study affirm a significant role for BIs, as a component of SBIRT, in motivating and facilitating
individuals’ admission to specialty treatment.

5.7. Future Research
Future research should investigate the extent to which BIs and BIs/RTs, as components of SBIRT,
facilitate admission to specialty substance abuse treatment and improve outcomes related to
specialty treatment and health. Further analyses on association between admission to specialty
treatment and clinical outcomes are warranted. Future research is needed to better understand how
to incorporate referrals to specialty treatment within BIs for individuals screening at low- to
moderate-risk, in addition to individuals screening at high-risk. Future research should utilize
longer-term follow-up periods (beyond one-year post-SBIRT services) to analyze impacts of BI
and BI/RT on admission to specialty substance abuse treatment, length of stay and outcomes of
specialty substance abuse treatment, and other health outcomes. Future analysis should also look
at cost-effectiveness of BI and BI/RT and its impact on utilization of other services, including
hospital/emergency department. Additional research on the ASSIST and scoring associated with
substance abuse level of risk would be useful. Research on how to best deliver BI and BI/RTs to
further increase post-SBIRT admissions to specialty treatment is warranted. Finally, future
research should consider use of a randomized controlled study design to further investigate BI and
BI/RT role.
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5.8. Conclusion
In conclusion, SBIRT provides early identification and intervention with individuals who are at
risk for substance abuse. The role of BI and the substantially significant role of BI/RT, as
components of SBIRT, is confirmed as a promising approach for early intervention for substance
use disorders, in addition for recovery management for individuals with pre-SBIRT specialty
treatment history. Wider dissemination of BI and BI/RT, as components of SBIRT, can have a
significant impact on healthcare and societal costs associated with substance abuse.

APPENDICES
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APPENDIX 1: WHO ASSIST
WHO  ASSIST    
The questions I’m going to ask you relate to your experiences with alcohol, cigarettes, and other drugs. Some of the substances
we’ll talk about can be prescribed by a doctor or dentist (like pain medications). But I am only concerned with those if you have
taken them for reasons other than prescribed, or in different doses than prescribed. This information is an important part of your
medical history and will help us in our mission to give you the most appropriate and comprehensive care.
I am interested in knowing about the substances you have used in your lifetime as well as those you have used in the past 3
months.
1.   In  your  life,  which  of  the  following  substances  have  you  ever  used?    
Please  report  Nonmedical  use  only:  (Do  not  record  medications  that  are  used  as  prescribed  by  
a  doctor).  

No  

Yes  

m.   Tobacco  products  such  as  cigarettes,  chewing  tobacco,  cigars,  etc.  

0  

3  

n.   Alcoholic  beverages  such  as  beer,  wine,  hard  liquor,  etc.  

0  

3

o.   Marijuana,  pot,  grass,  reefer,  weed,  ganja,  hash,  chronic,  gangster,  joints,  blunts,  Mary  Jane,  etc.  

0  

3

p.   Cocaine  or  Crack,  coke,  blow,  snow,  flake,  toot,  rock,  etc.  

0  

3
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q.   Prescription  stimulants  such  as  Ritalin,  Concerta,  Adderall,  Dexedrine,  diet  pills,  etc.    

0  

3

r.  

Methamphetamine,  uppers,  speed,  crystal  meth,  ice,  chalk,  glass,  fire,  crank,  etc.    

0  

3

s.  

Inhalants  or  anything  you  might  huff,  like  glue,  correction  fluid,  gasoline,  butane,  paint  thinner,  
lighter  fluid,  spray  paint,  poppers,  snappers,  Rush,  Nitrous  Oxide,  laughing  gas,  whippets,  etc.  

0  

3

t.  

Sedatives  or  sleeping  pills  such  as  Diazepam  (Valium),  Lorazepam  (Ativan),  Alprazolam  (Xanax),  
Triazolam,  Halcion,  Librium,  Restoril,  Estazolam  (ProSom),  Rohypnol  (roofies,  roche,  cope),  
Serepax,  Seconal,  pentobarbital  sodium  (Nembutal),  Phenobarbital,  mephobarbitol  (Mebacut),  
GHB  (Grievous  Bodily  Harm,  Georgia  Home  Boy,  Liquid  X,  Liquid  Ecstasy),  Ketamine  (Special  K,  
Vitamin  K),  downers,  tranquilizers,  sedatives,  hypnotics,  etc.  

0  

3

u.   Hallucinogens/psychedelics,  LSD  (acid,  Boomers,  Yellow  Sunshine),  mushrooms,  mescaline,  PCP  
(Angel  Dust,  Ozone,  Wack,  Rocket  Fuel),  MDMA  (Ecstasy,  XTC,  Adam,  X),  wet,  illy,  etc.  

0  

3

v.   Prescription  pain  medication  such  as  fentanyl,  oxycodone,  OxyContin,  Percocet,  hydrocodone,  
Vicodin,  methadone,  buprenorphine,  codeine,  Darvon,  Dilaudid,  Demerol,  Lortab,  Talwin-‐Nx,  
Tylenol-‐2,  -‐3,  -‐4,  morphine,  non-‐prescription  methadone,  etc.  

0  

3

w.   Heroin,  opium,  Smack,  H,  Junk  ,  Skag  

0  

3

x.   Other  drug:    Something  not  listed  here?  Please  specify:  ____________________________  

0  

3

If  the  patient  says  “No”  for  all  items  in  Question  1,  reinforce  abstinence.  Screening  is  complete.  
If  the  patient  says  “Yes”  to  any  of  the  substances,  ask  Question  2  for  those  substances  ever  used.    

§  
§  
  

Once  or  
Twice  

Monthly  

Weekly  

a.   Tobacco  products  or  cigarettes     

0  

2  

3  

4  

6  

b.   Alcoholic  beverages    

0  

2  

3  

4  

6  

c.  

0  

2  

3  

4  

6  

d.   Cocaine  or  Crack    

0  

2  

3  

4  

6  

e.   Prescription  stimulants    

0  

2  

3  

4  

6  

f.  

0  

2  

3  

4  

6  

g.   Inhalants    

0  

2  

3  

4  

6  

h.   Sedatives  or  sleeping  pills    

0  

2  

3  

4  

6  

i.  

Hallucinogens    

0  

2  

3  

4  

6  

j.  

Prescription  pain  medication  

0  

2  

3  

4  

6  

k.   Heroin  

0  

2  

3  

4  

6  

l.  

0  

2  

3  

4  

6  

Marijuana    

Methamphetamine    

Other  –  specify:  
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Daily  or  
Almost  
Daily  

Never  

2.   In  the  past  three  months,  how  often  have  you  used  the  substances  
you  mentioned  (first  drug,  second  drug,  etc)?	
  

  

For  patients  who  report  “Never”  having  used  any  substance  in  the  past  3  months:  Go  to  Question  6.  
If  any  substances  in  Question  2  were  used  in  the  previous  three  months,  ask  Question  3  for  each  substance  used.  

Once  or  
Twice  

Monthly  

Weekly  

a.   Tobacco  products  or  cigarettes  

0  

3  

4  

5  

6  

b.   Alcoholic  beverages    

0  

3  

4  

5  

6  

c.  

Marijuana    

0  

3  

4  

5  

6  

d.   Cocaine  or  Crack  

0  

3  

4  

5  

6  

e.   Prescription  stimulants    

0  

3  

4  

5  

6  

f.  

0  

3  

4  

5  

6  

g.   Inhalants    

0  

3  

4  

5  

6  

h.   Sedatives  or  sleeping  pills    

0  

3  

4  

5  

6  

i.  

Hallucinogens    

0  

3  

4  

5  

6  

j.  

Prescription  pain  medication  

0  

3  

4  

5  

6  

k.   Heroin  

0  

3  

4  

5  

6  

l.  

0  

3  

4  

5  

6  

3.   In  the  past  3  months,  how  often  have  you  had  a  strong  desire  or  
urge  to  use  (first  drug,  second  drug,  etc)?	
  

Methamphetamine    

Other  –  specify:  

Daily  or  
Almost  
Daily  

Never  

§  

Once  or  
Twice  

Monthly  

Weekly  

0  

4  

5  

6  

7  

b.   Alcoholic  beverages    

0  

4  

5  

6  

7  

c.  

Marijuana    

0  

4  

5  

6  

7  

d.   Cocaine  or  Crack  

0  

4  

5  

6  

7  

e.   Prescription  stimulants    

0  

4  

5  

6  

7  

f.  

0  

4  

5  

6  

7  

g.   Inhalants    

0  

4  

5  

6  

7  

h.   Sedatives  or  sleeping  pills    

0  

4  

5  

6  

7  

i.  

Hallucinogens    

0  

4  

5  

6  

7  

j.  

Prescription  pain  medication  

0  

4  

5  

6  

7  

k.   Heroin  

0  

4  

5  

6  

7  

l.  

0  

4  

5  

6  

7  

Once  or  
Twice  

Monthly  

Weekly  

Methamphetamine    

Other  –  specify:  

5.   During  the  past  3  months,  how  often  have  you  failed  to  do  what  
was  normally  expected  of  you  because  of  your  use  of  (first  drug,  
second  drug,  etc)?  
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Daily  or  
Almost  
Daily  

4.   During  the  past  3  months,  how  often  has  your  use  of  (first  drug,  
second  drug,  etc)  led  to  health,  social,  legal  or  financial  problems?  

Daily  or  
Almost  
Daily  

Never  

a.   Tobacco  products  or  cigarettes  

Never  

  
  
  

a.   Tobacco  products  or  cigarettes  

  

  

  

  

  

b.   Alcoholic  beverages    

0  

5  

6  

7  

8  

c.  

Marijuana    

0  

5  

6  

7  

8  

d.   Cocaine  or  Crack  

0  

5  

6  

7  

8  

e.   Prescription  stimulants    

0  

5  

6  

7  

8  

f.  

0  

5  

6  

7  

8  

g.   Inhalants    

0  

5  

6  

7  

8  

h.   Sedatives  or  sleeping  pills    

0  

5  

6  

7  

8  

i.  

Hallucinogens    

0  

5  

6  

7  

8  

j.  

Prescription  pain  medication  

0  

5  

6  

7  

8  

k.   Heroin  

0  

5  

6  

7  

8  

l.  

0  

5  

6  

7  

8  

Methamphetamine    

Other  –  specify:  

Ask  Questions  6  &  7  for  all  substances  ever  used  (i.e.,  those  endorsed  in  Question  1).  

§  

6.   Has  a  friend  or  relative  or  anyone  else  ever  expressed  concern  
about  your  use  of  (first  drug,  second  drug,  etc)?  

No,  
never  

Yes,  in  the  
past  3  
months  

Yes,  but  not  
in  the  past  3  
months  

a.   Tobacco  products  or  cigarettes  

0  

6  

3  

b.   Alcoholic  beverages    

0  

6  

3  

c.  

Marijuana    

0  

6  

3  

d.   Cocaine  or  Crack  

0  

6  

3  

e.   Prescription  stimulants    

0  

6  

3  

f.  

0  

6  

3  

g.   Inhalants    

0  

6  

3  

h.   Sedatives  or  sleeping  pills    

0  

6  

3  

i.  

Hallucinogens    

0  

6  

3  

j.  

Prescription  pain  medication  

0  

6  

3  

k.   Heroin  

0  

6  

3  

l.  

0  

6  

3  

Methamphetamine    

Other  –  specify:  
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7.   Have  you  ever  tried  and  failed  to  control,  cut  down  or  stop  using  
(first  drug,  second  drug,  etc)?  

No,  
never  

Yes,  in  the  
past  3  
months    

Yes,  but  not  
in  the  past  3  
months    

a.   Tobacco  products  or  cigarettes  

0  

6  

3  

b.   Alcoholic  beverages    

0  

6  

3  

c.  

Marijuana    

0  

6  

3  

d.   Cocaine  or  Crack  

0  

6  

3  

e.   Prescription  stimulants    

0  

6  

3  

f.  

0  

6  

3  

g.   Inhalants    

0  

6  

3  

h.   Sedatives  or  sleeping  pills    

0  

6  

3  

i.  

Hallucinogens    

0  

6  

3  

j.  

Prescription  pain  medication  

0  

6  

3  

k.   Heroin  

0  

6  

3  

l.  

0  

6  

3  

Methamphetamine    

Other  –  specify:  
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Pa t ie nt    Fe e d ba c k   Re por t  

  
  

Risk  Level  
Low	
  

Moderate	
  

High	
  

Your  
Score  

a.   Tobacco  products  such  as  cigarettes,  chewing  tobacco,  cigars,  etc.  

0  -‐  3  

4  -‐  26  

27  +  

  

b.   Alcoholic  beverages  such  as  beer,  wine,  hard  liquor,  etc.  

0  -‐  10  

11  -‐  26  

27  +  

  

Marijuana,  pot,  grass,  reefer,  weed,  ganja,  hash,  chronic,  
gangster,  joints,  blunts,  Mary  Jane,  etc.  

0  -‐  3  

4  -‐  26  

27  +  

  

d.   Cocaine  or  Crack,  coke,  blow,  snow,  flake,  toot,  rock,  etc.  

0  -‐  3  

4  -‐  26  

27  +  

  

e.   Prescription  stimulants  such  as  Ritalin,  Concerta,  Adderall,  
Dexedrine,  diet  pills,  etc.    

0  -‐  3  

4  -‐  26  

27  +  

  

Methamphetamine,  uppers,  speed,  crystal  meth,  ice,  chalk,  glass,  
fire,  crank,  etc.    

0  -‐  3  

4  -‐  26  

27  +  

  

g.   Inhalants  or  anything  you  might  huff,  like  glue,  correction  fluid,  
gasoline,  butane,  paint  thinner,  lighter  fluid,  spray  paint,  poppers,  
snappers,  Rush,  Nitrous  Oxide,  laughing  gas,  whippets,  etc.  

0  -‐  3  

4  -‐  26  

27  +  

  

h.   Sedatives  or  sleeping  pills  such  as  Diazepam  (Valium),  Lorazepam  
(Ativan),  Alprazolam  (Xanax),  Triazolam,  Halcion,  Librium,  Restoril,  
Estazolam  (ProSom),  Rohypnol  (roofies,  roche,  cope),  Serepax,  
Seconal,  pentobarbital  sodium  (Nembutal),  Phenobarbital,  
mephobarbitol  (Mebacut),  GHB  (Grievous  Bodily  Harm,  Georgia  
Home  Boy,  Liquid  X,  Liquid  Ecstasy),  Ketamine  (Special  K,  Vitamin  
K),  downers,  tranquilizers,  sedatives,  hypnotics,  etc.  

0  -‐  3  

4  -‐  26  

27  +  

  

Hallucinogens/psychedelics,  LSD  (acid,  Boomers,  Yellow  
Sunshine),  mushrooms,  mescaline,  PCP  (Angel  Dust,  Ozone,  Wack,  
Rocket  Fuel),  MDMA  (Ecstasy,  XTC,  Adam,  X),  wet,  illy,  etc.  

0  -‐  3  

4  -‐  26  

27  +  

  

Prescription  pain  medication  such  as  fentanyl,  oxycodone,  
OxyContin,  Percocet,  hydrocodone,  Vicodin,  methadone,  
buprenorphine,  codeine,  Darvon,  Dilaudid,  Demerol,  Lortab,  
Talwin-‐Nx,  Tylenol-‐2,  -‐3,  -‐4,  morphine,  non-‐prescription  
methadone,  etc.  

0  -‐  3  

4  -‐  26  

27  +  

  

k.   Heroin,  opium,  Smack,  H,  Junk  ,  Skag  

0  -‐  3  

4  -‐  26  

27  +  

  

l.  

0  -‐  3  

4  -‐  26  

27  +  

  

Substance  

c.  

f.  

i.  

j.  

  

  

Other  drug:    Something  not  listed  here?  Please  specify:    
What do your scores mean?

Low:   You are at low risk of health and other problems from your current pattern of use.
Moderate:   You are at risk of health and other problems from your current pattern of substance use.
High:   You are at high risk of experiencing severe problems (health, social, financial, legal, relationship) as
a result of your current pattern of use and are likely to be dependent.
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APPENDIX 2: Scoring the ASSIST
Substance Specific Scores.
Sum across questions 2 – 7 for each substance category separately.
For example, the Marijuana Specific Score would be: 2c+3c+4c+5c+6c+7c
Maximum score for tobacco = 31 (Q5 is not asked)
Maximum score for each of the other drug categories = 39
Risk Level

ASSIST
Score

Substance

Low

LowModerate

HighModerate

High

SF

BI

BT

RT

a.   Tobacco products or cigarettes

0-3

4 - 19

20 - 26

27+

b.   Alcoholic beverages

0 - 10

11 - 19

20 - 26

27+

c.   Marijuana

0-3

4 – 19

20 - 26

27+

d.   Cocaine or Crack

0-3

4 – 19

20 - 26

27+

e.   Prescription stimulants

0-3

4 – 19

20 - 26

27+

f.   Methamphetamine

0-3

4 - 19

20 - 26

27+

g.   Inhalants

0-3

4 - 19

20 - 26

27+

h.   Sedatives or sleeping pills

0-3

4 - 19

20 - 26

27+

i.   Hallucinogens

0-3

4 - 19

20 - 26

27+

j.   Prescription pain medication

0-3

4 - 19

20 - 26

27+

k.   Heroin

0-3

4 - 19

20 - 26

27+

l.   Other – specify

0-3

4 - 19

20 - 26

27+

SBIRT Class Code

What do your scores mean?
Low:
You are at low risk of health and other problems from your current pattern of use.
Moderate:

You are at risk of health and other problems from your current pattern of substance use.

High:

You are at high risk of experiencing severe problems (health, social, financial, legal,
relationship) as a result of your current pattern of use and are likely to be dependent.
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